

LUCY ANN GODLEY, M.D., Ph.D.
CURRICULUM VITAE

PERSONAL DATA

Office: The University of Chicago
 Section of Hematology/Oncology
 5841 S. Maryland Ave. (MC 2115)
 Chicago, IL 60637
 Phone: (773) 702-4140
 FAX: (773) 702-9268
 Pager: (773) 753-1880, p5141
 Email: lgodley@medicine.bsd.uchicago.edu

Home: 5540 N. Magnolia Ave.
 Chicago, IL 60640
Phone: (773) 230-5073

Marital status: Married to Alfonso Mondragón
Children: Sofia (5/27/2000)
 Julian (11/11/2002)

ACADEMIC TRAINING*Education*

- 1980-1984 Amity Regional Senior High School, Woodbridge, CT
 Graduated valedictorian from a class of 400 students
- 1984-1988 B.A. Harvard and Radcliffe Colleges, Cambridge, MA
summa cum laude in Biochemical Sciences
 Recipient of the Elizabeth Cary Agassiz and the Harvard College Scholarships
 Dean's list each semester
 Henderson prize for outstanding biochemistry thesis
- 1988-1995 Ph.D. University of California, San Francisco, San Francisco, CA
 Medical Scientist Training Program and Pre-IRTA Fellow, National Institutes of Health,
 NCI, Bethesda, MD
 Thesis: The effects of altered p53 expression on tumorigenesis and development
 Advisor: Harold E. Varmus, M.D.
- 1996-1997 M.D. Northwestern University School of Medicine, Chicago, IL

Post-doctoral training

- 1997-2003 The University of Chicago Clinical Investigator Pathway, Chicago, IL
 Internal Medicine Residency followed by fellowship in Hematology/Oncology
 Research Mentor: Michelle M. Le Beau, Ph.D.

ACADEMIC APPOINTMENTS

The University of Chicago, Chicago, IL

- 2003-2010 Assistant Professor, Section of Hematology/Oncology
 2010-2014 Associate Professor, Section of Hematology/Oncology
 2015-present Professor, Section of Hematology/Oncology, Department of Medicine
 2016-present Professor, Department of Human Genetics (secondary appointment)
 2020-present Hospira Foundation Professor in Oncology

Ph.D.-Granting Committee, Program, Institute, and Center Appointments

- 2003-present The University of Chicago Comprehensive Cancer Center
 2004-present Committee on Cancer Biology

Leadership

- 2010-2011 Vice Chair, Physician Scientist Development Program
 2005-2018 Steering Committee Member, Medical Scientist Training Program
 2011-2018 Associate Director for Admissions, Medical Scientist Training Program
 2010-2015 Vice Chair, Scientific Accrual and Monitoring Committee, Comprehensive Cancer Center
 2015-present Chair, Scientific Accrual and Monitoring Committee, Comprehensive Cancer Center
 2014-2016 Co-Leader, Hematopoiesis and Hematological Malignancies Program, Comprehensive
 Cancer Center
 2014-present Medical Director, Cancer Cytogenetics Laboratory
 2016-present Director, Chicago Biomedical Consortium (CBC) for The University of Chicago
 2019-present Member, University Senate

Scientific Advisory Boards

2019-present Invitae, Inc.

2019-present Forbeck Foundation

LICENSURE

IL Physician License 036-100580 (*valid until 7/31/2020*)

IL Controlled Substance License 336-061031 (*valid until 7/31/2020*)

DEA Registration Number BG6473564 (*valid until 9/30/2020*)

BOARD CERTIFICATION

American Board of Hematology (*valid until 2023*)

American Board of Medical Oncology (*valid until 2025*)

American Board of Internal Medicine (*expired 2010*)

HONORS and AWARDS

- 1984-1988 Elizabeth Cary Agassiz Scholarship and Harvard College Scholarship (Dean's List) each semester, Harvard University
- 1988 Henderson Prize for the most outstanding senior thesis in Biochemistry, Harvard University
- 1988 Graduated *summa cum laude*, Harvard University
- 1988 Phi Beta Kappa, Iota Chapter of Radcliffe College
- 2002 Howard Hughes Medical Institute Physician Postdoctoral Award
- 2002 Cancer and Leukemia Group B (CALGB) Foundation Clinical Research Award
- 2003 American Society of Clinical Oncology Young Investigator Award
- 2004 Cancer Research Foundation Young Investigator Award
- 2004 The Schweppe Foundation Career Development Award
- 2005 The Kimmel Scholar Award
- 2012 Inducted into the American Society of Clinical Investigation
- 2013 Leif B. Sorensen, MD Faculty Research Award
- 2015 The Leukemia and Lymphoma Society Hematology Service Award
- 2018 The Pamela B. Katten Memorial Leukemia Research Foundation Researcher of the Year
- 2019 Outstanding Mission Focused Health Care Professional, IL Chapter of the Leukemia and Lymphoma Society for service to the Chicago Hispanic community
- 2020 Distinguished Senior Investigator Award, Biological Sciences Division, University of Chicago
Keith Minor Ford Memorial Lecture, University of Rochester Medical Center

PROFESSIONAL MEMBERSHIPS and SERVICE

- since 2003 American Society of Hematology
- since 2003 American Association for Cancer Research
- since 2003 American Society of Clinical Oncology
- 2009-2010 NIH Study Section Special Emphasis Panels ZRG1 CBSS-P 08 F and ZCA1 SRLB-R (J1)
- 2009-2010 NIH Study Section: Cancer Genetics Ad Hoc Reviewer
- 2011-2013 NIH Study Section: Cancer Genetics Permanent Member
- 2013 Council of Faculty and Academic Societies
- 2013, 2015 American Society of Hematology Scholar Award Selection Committee
- 2012-2017 American Society of Hematology Scientific Committee on Myeloid Neoplasia
- 2016 Vice Chair
- 2017 Chair
- 2015-2016 Research Education Committee, Society of Hematologic Oncology
- 2014-2016 American Association for Cancer Research Molecular Biology in Clinical Oncology Faculty Member
- 2014-2019 Damon Runyon Cancer Research Fellowship Committee Member
- 2015-present Damon Runyon Physician-Scientist Training Award Committee Member
- 2016-present Chair, American Society of Hematology Friday Scientific Workshop on Inherited Hematopoietic Malignancies
- 2018-present Co-Chair, ClinGen Myeloid Malignancy Variant Curation Expert Panel

2021-present Vice Chair, American Society of Hematology Subcommittee on Precision Medicine

REVIEW EXPERIENCE

Journals- Editorial Boards

2009-2014 *Leukemia and Lymphoma*
2013-present *Clinical Cancer Research*
2017-2019 *Blood*

Ad Hoc Reviewer: *Blood, Cancer Research, Leukemia Research, New England Journal of Medicine, Proc. Natl. Acad. Sci. USA.*

Peer Review Panels

2007-2008 Leukemia Research Foundation
2008-2009 Physician-Scientist Early Career Award Review Committee for the Howard Hughes Medical Institute
2008-2009 Cancer Research UK, Clinical Trial Awards and Advisory Committee
2008-2011 The ASCO Cancer Foundation Grants Selection Committee
2009 NIH/CSR Review Special Emphasis Panel
2010 NIH/NCI Special Emphasis Panel ZCA1 SRLB-R (J1)
2010 NIH Cancer Genetics Study Section, Ad Hoc reviewer
2011-2013 NIH Cancer Genetics Study Section, Permanent reviewer
2014 Leukemia and Lymphoma Society
2015 American Society of Hematology
2015-2019 Damon Runyon Cancer Research Fellowship
2015-present Damon Runyon Physician-Scientist Training Award
2016-present Taub Foundation (currently Review Chair)

INVITED LECTURES

Scientific with national/international attendees

Jan 13, 2007	Workshop Speaker	<i>Johns Hopkins</i> Workshop on Clinical Targeting of Epigenetic Changes in Cancer Therapeutics, Phoenix, AZ. Biological impact of aberrant DNMT expression.
Apr 17, 2007	Invited Speaker	<i>American Association for Cancer Research</i> national meeting, Los Angeles, CA. A truncated DNMT3B protein expressed in cancer cells disrupts murine embryonic development.
Dec 4, 2007	Invited Speaker	<i>American Society of Cell Biology</i> national meeting, Washington, D.C. A truncated DNMT3B protein expressed in cancer cells disrupts embryonic development in transgenic mice.
Jun 7, 2010	Co-Chair Poster Disc.	<i>American Society of Clinical Oncology</i> national meeting, Chicago, IL. Leukemia, Myelodysplasia, and Transplantation Poster Discussion
Oct 25, 2010	Invited Speaker	<i>11th Annual Principal Investigator's Meeting</i> for the Innovative Molecular Analysis Technologies (IMAT) Program, San Francisco, CA. Defining epigenetic proteomes using novel crosslinking agents.
Jan 16, 2011	Workshop Speaker	<i>5th Biennial Workshop on the Clinical Translation of Epigenetics in Cancer Therapy</i> , San Diego, CA. Determining the epigenetic function of 5-hydroxymethylcytosine using a novel chemical labeling strategy.

Dec 9, 2011	Workshop Speaker	<i>2011 Workshop on Myeloid Development</i> , San Diego, CA. 5-Hydroxymethylcytosine in normal and malignant hematopoiesis.
Jun 19, 2012	Invited Speaker	<i>Institut Gustave Roussy</i> , Paris, France. The genetic and epigenetic landscape of myeloid malignancies.
Jun 22, 2012	Invited Speaker	<i>University of Paris</i> , Paris, France. The genetic and epigenetic landscape of myeloid malignancies.
Dec 8, 2012	Invited Speaker	<i>American Society of Hematology</i> annual meeting, Atlanta, GA. 5-Hydroxymethylcytosine control of hematopoiesis.
Jan 20, 2013	Workshop Speaker	<i>6th Biennial Workshop on the Clinical Translation of Epigenetics in Cancer Therapy</i> , Asheville, NC. 5-Hydroxymethylcytosine at gene regulatory regions directs stem cell commitment during erythropoiesis.
May 30, 2013	Invited Speaker	<i>New York Academy of Sciences</i> : "The bone marrow niche, stem cells, and leukemia: Impact of drugs, chemicals, and the environment", New York, NY. Epigenetic mechanisms and therapeutics.
Jun 26, 2013	Invited Speaker	<i>Clinical Epigenome Conference</i> , San Francisco. Defining the epigenetic landscape during normal and malignant hematopoiesis.
Jan 10, 2014	Symposium Speaker	<i>Keystone Symposium</i> : Sensing and signaling of hypoxia: interfaces with biology and medicine, Breckenridge, CO. TET1-mediated hydroxymethylation facilitates hypoxic gene induction in neuroblastoma.
Mar 19, 2014	Symposium Speaker	<i>Keystone Symposium</i> : Tumor Metabolism, Whistler, Canada. Regulation of hematopoiesis by 5-hydroxymethylcytosine.
Apr 5, 2014	Invited Speaker	<i>American Association for Cancer Research</i> , annual meeting, San Diego, CA. Methods to distinguish 5-methylcytosine from 5-hydroxymethylcytosine.
Nov 13, 2014	Plenary Speaker	<i>Association for Molecular Pathology</i> annual meeting, Washington, DC. 5-Hydroxymethylcytosine control of hematopoiesis.
Feb 18, 2015	Invited Speaker	<i>Molecular Med Tri-Con Meeting</i> , San Francisco, CA (diagnostics and drug discovery). Control of cell differentiation and phenotype by 5-hydroxymethylcytosine.
May 1, 2015	Invited Speaker	<i>Myelodysplastic Syndrome 2015 Summit</i> of the American Society of Hematology, Washington, DC. Inherited predisposition to myeloid malignancies.
Jul 27, 2015	Symposium Speaker	<i>FASEB Science Research Conference</i> : Hematologic Malignancies, Saxtons River, VT. The genetic and epigenetic drivers of myeloid malignancies.
Dec 2, 2016	Workshop Chair	<i>American Society of Hematology Friday Workshop on Inherited Hematopoietic Malignancies</i> , San Diego, CA.
Feb 16, 2017	Invited Speaker	<i>Lambrechts Laboratory</i> , University of Leuven, Belgium. Control of cancer cell phenotype by 5-hydroxymethylcytosine.

Apr 3, 2017	Meet-the-Expert	<i>American Association for Cancer Research Annual Meeting, Washington, DC. Control of cancer cell phenotype by covalent cytosine modifications.</i>
Mar 22, 2018	Workshop Chair	<i>AA MDS Foundation Biannual Meeting, Rockville, MD. Introduction to the inherited BMF and leukemia predisposition syndromes: What are the open clinical and research questions?</i>
Sept 11, 2019	Session Chair/Speaker	<i>Society of Hematologic Oncology Annual Meeting, Houston, TX. Pre-MDS: CHIP, ICUS, and CCUS.</i>
Dec 8, 2019	Invited Speaker	<i>American Society of Hematology Annual Meeting, Orlando, FL. Application of microarray and large datasets to hematology and bioinformatics.</i>
Dec 13, 2019	Invited Speaker	<i>Varmus Symposium, Cold Spring Harbor Laboratory, NY. Germline predisposition to hematopoietic malignancies.</i>
Feb 18, 2020	Invited Speaker	<i>Stanford Immunology Seminar Series, Palo Alto, CA. How germline and somatic mutations regulate hematopoiesis through inflammation.</i>
Nov 5, 2020	Invited Speaker	<i>StandUpToCancer Innovation Summit: Interface of Epigenetics and Immunotherapy, Los Angeles, CA (virtual). Using knowledge of epigenetics to change cellular phenotypes.</i>
Nov 14-15, 2020	Invited Moderator and Speaker	<i>European School of Haematology and European Society for Blood and Marrow Transplantation: Bone Marrow Failure Disorders: From the cell to the cure of the disease, Paris, France (virtual). Genetic predisposition for myeloid malignancies: clinical management.</i>
Nov 21, 2020	Keynote Speaker	<i>Windsor Cancer Research Group 5th Biennial International Cancer Research Conference, Windsor, Canada (virtual). Germline predisposition to hematopoietic malignancies.</i>
Feb 4, 2021	Grand Rounds Speaker	<i>Memorial Sloan Kettering Department of Pediatrics Grand Rounds, New York, NY (virtual). Germline predisposition to hematopoietic malignancies.</i>
Feb 5, 2021	Grand Rounds Speaker	<i>National Cancer Institute Center for Cancer Research Grand Rounds, NIH, Bethesda, MD (virtual). Germline predisposition to hematopoietic malignancies.</i>

Clinical with national/international attendees

Feb 5, 2011	Board Review Lecturer	<i>Mexican Hematology Society Board Review course, Mexico City, Mexico. Leucemia myeloide aguda en adultos (Acute myeloid leukemia in adults).</i>
Mar 21, 2015	Invited Speaker	<i>Pediatric Oncology Third International Meeting, Barretos, Brazil. Germline predisposition to hematopoietic malignancies.</i>
Sep 11, 2015	Invited Speaker	<i>European School of Haematology: Molecular and Translational Advances in Biology and Treatment International Conference, Budapest, Hungary. Germline mutations and AML. Acute Myeloid Leukemia.</i>
Sep 19, 2015	Invited Speaker	<i>Society of Hematologic Oncology annual meeting, Houston, TX. Germline predisposition to myeloid malignancies.</i>

Sep 21, 2015	Invited Speaker	<i>International Association for Comparative Research on Leukemia and Related Diseases</i> annual meeting, Paris, France. Factors Predisposing to Hematological Malignancies.
Oct 24, 2015	Conference Speaker	<i>Leukemia Predisposing Genes Conference</i> , Perugia, Italy. Germline predisposition to myeloid malignancies.
Mar 17, 2016	Symposium Speaker	<i>Aplastic Anemia and MDS International Foundation: 5th International Bone Marrow Failure Disease Scientific Symposium</i> , Rockville, MD. Familial myeloid diseases.
May 4, 2016	Workshop Speaker	<i>11th International workshop on molecular aspects of myeloid stem cell development and leukemia</i> , Cincinnati, OH. Inherited predisposition to myeloid malignancies.
Sep 10, 2016	Conference Speaker	<i>Canadian Conference on Myelodysplastic Syndromes</i> , Quebec, Canada. Born with bad genes.
Feb 16, 2017	Invited Speaker	<i>Cliniques Universitaires Saint-Luc</i> , Section of Hematology, Brussels, Belgium. Clinical implications of familial leukemia syndromes.
Feb 17, 2017	Plenary Speaker	<i>Belgian Society of Human Genetics</i> annual meeting, Louvain-la-Neuve, Belgium. Inherited predisposition to hematopoietic malignancies.
May 8, 2017	Co-Chair/Presenter	<i>American Association of Cancer Research: Hematologic Malignancies- Translating discoveries to novel therapies</i> , Boston, MA. Genetic predisposition to hematopoietic malignancies.
May 18, 2017	Grand Rounds Speaker	<i>University of Toronto, Department of Hematology/Oncology</i> , Toronto, Canada. The role of germline mutations in hematopoietic malignancies.
Jun 3, 2017	Plenary Speaker	<i>2017 Liangjiang International Pediatric Forum</i> , Chongqing, China. Current progress in inherited leukemias.
Sep 7, 2017	Plenary Speaker	<i>Society for Hematopathology and the European Association for Haematopathology 2017 Workshop: Molecular Genetics of Hematopoietic Neoplasms</i> , Chicago, IL. Genetic predisposition syndromes in myeloid malignancies.
Sep 9, 2017	Invited Speaker	<i>2017 ASH Meeting on Hematologic Malignancies</i> , Chicago, IL. How I Treat AML: When Patients Ask If AML Can Be Inherited, What Do I Tell Them?
Feb 21, 2019	Meet-the-Professor	<i>2019 Transplantation & Cellular Therapy Annual Meeting</i> , Houston, TX. Germline predisposition to bone marrow failure and hematopoietic malignancies.
Mar 1, 2019	Invited Speaker	<i>XVII Annual Conference on Evidence Based Management of Cancers in India: Clinical Genomics in Hemato-Oncology</i> , Mumbai, India. Use of next-generation sequencing to diagnose individuals at risk for inherited myeloid neoplasms.
Mar 2, 2019	Invited Speaker	<i>Tata Memorial Hospital</i> , Mumbai, India. How do I manage individuals at risk for inherited myeloid malignancies?
Mar 14, 2019	Invited Speaker	<i>Korean Society of Hematology Annual Meeting</i> , Seoul, Korea. Inherited hematologic malignancies.

Apr 1, 2019	Invited Speaker	<i>American Association for Cancer Research Annual Meeting, Atlanta, Georgia. Diagnosis and management of patients with germline predisposition to hematopoietic malignancies.</i>
Jul 15, 2019	Invited Speaker	<i>Hematology/Oncology Grand Rounds Speaker, King Hussein Cancer Center, Amman, Jordan. Identifying patients and families with inherited hematopoietic malignancies.</i>
Oct 15, 2019	Invited Speaker	<i>1st Annual Human Genomics Symposium, National University and Genome Institute of Singapore, Singapore. Germline predisposition to hematopoietic malignancies.</i>
Oct 24, 2019	Invited Speaker	<i>5th International Conference Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment, European School of Haematology, Estoril, Portugal. Germline predisposition to hematopoietic malignancies.</i>
Oct 28, 2019	Invited Speaker	<i>Erasmus Medical Center Hematology Lecture, Rotterdam, The Netherlands. Germline predisposition to hematopoietic malignancies.</i>
Nov 15, 2019	Invited Speaker	<i>9th Barossa Meeting: Cell Signaling in Cancer Medicine, Barossa, Australia. Germline predisposition to hematopoietic malignancies.</i>
Nov 18, 2019	Invited Speaker	<i>SA Pathology Cancer Biology Seminar Series, Adelaide, Australia. Germline predisposition to hematopoietic malignancies.</i>
Nov 22, 2019	Invited Speaker	<i>Royal Adelaide Hospital Haematology Grand Rounds, Adelaide, Australia. Germline predisposition to hematopoietic malignancies.</i>
Jan 28, 2020	Invited Speaker	<i>Uppsala Hematology Department Grand Rounds, Uppsala, Sweden. Germline predisposition to hematopoietic malignancies.</i>
Jan 29, 2020	Keynote Speaker	<i>Annual Meeting of the Swedish Association of Clinical Genetics, Stockholm, Sweden. Germline predisposition to hematopoietic malignancies.</i>
Feb 24, 2020	Invited Speaker	<i>2nd Biennial Miami Leukemia Symposium, Miami, FL. Germline predisposition to myeloid disorders.</i>
Feb 28, 2020	Keynote Speaker	<i>7th International Conference of the Jordanian Society of Hematology, Amman, Jordan. Germline predisposition to hematopoietic malignancies.</i>
Jun 30, 2020	Invited Speaker	<i>European School of Haematology: 2nd How to Diagnose and Treat Acute Leukemia, Budapest, Hungary (virtual). Germline predisposition to AML.</i>
Oct 7, 2020	Invited Speaker	<i>Pediatric Hematology Grand Rounds, Centre de recherche, CHU Sainte-Justine, Montreal, Canada (virtual). Germline predisposition to hematopoietic malignancies.</i>

Scientific with regional attendees

Nov, 2005	Symposium Speaker	<i>University of Chicago: Symposium to honor Dr. Janet Rowley's 80th birthday. From translocations to the epigenome: the role of chromatin structure in myeloid malignancies.</i>
-----------	-------------------	---

Apr 13, 2007	Workshop Speaker	<i>American Physician Scientists Association, Laboratory Leadership in Science Workshop, Chicago, IL.</i>
Aug 25, 2007	Retreat Speaker	<i>University of Illinois at Urbana-Champaign, Annual retreat of the Medical Scholars Program, Monticello, IL.</i>
Oct 17, 2007	Grand Rounds Speaker	<i>MD Anderson Cancer Center, Leukemia Department Grand Rounds, Houston, TX. Probing the molecular basis for the abnormal DNA methylation patterns of cancer cells.</i>
Nov 17, 2008	Invited Speaker	<i>Indiana University, Medical Sciences Biomedical Colloquium, Bloomington, IN. The role of DNMT3B isoforms in mediating the abnormal DNA methylation patterns of cancer cells.</i>
Mar 30, 2009	Seminar Speaker	<i>Illinois Institute of Technology, Chicago, IL. Deciphering the molecular basis for the DNA methylation distribution that characterizes cancer cells.</i>
Jul 9 & 23, 2009	Invited Speaker	<i>National Youth Leadership Forum on Medicine. University of Illinois at Chicago, Chicago, IL.</i>
Jan 28, 2010	Seminar Speaker	<i>University of Alabama, Division of Hematology/Oncology. Birmingham, AL. Deciphering the molecular basis for the abnormal DNA methylation distribution of human cancers.</i>
Apr 26, 2010	Seminar Speaker	<i>Roswell Park Cancer Institute, Pharmacology and Therapeutics Seminar Series, Buffalo, NY. Testing the role of truncated DNMT3B proteins in mediating the abnormal DNA methylation patterns of cancer cells.</i>
Nov 9, 2010	Grand Rounds Speaker	<i>The University of Chicago, Pathology Grand Rounds, Chicago, IL. Defining the epigenomic landscape of cancer cells.</i>
Mar 3, 2011	Seminar Speaker	<i>Northwestern University, Chicago, IL. Defining the epigenomic landscape of cancer cells.</i>
Mar 10, 2011	Seminar Speaker	<i>Baylor College of Medicine, Houston, TX. Defining the epigenomic landscape of cancer cells.</i>
Mar 14, 2011	Invited Speaker	<i>Normal and Malignant Hematopoiesis Research Affinity Group sponsored by the Children's Hospital of Philadelphia Research Institute, Philadelphia, PA. Defining the epigenomic landscape of cancer cells.</i>
Jun 6, 2011	Seminar Speaker	<i>Northwestern University, Physical Sciences in Oncology Center, Evanston, IL. The role of hydroxymethylcytosine in normal and malignant hematopoiesis.</i>
Feb 9, 2012	Seminar Speaker	<i>University of Nebraska, Eppley Seminar Series, Omaha, NE. The role of DNMT3B in tumorigenesis.</i>
Mar 7, 2012	Seminar Speaker	<i>Medical College of Georgia, Augusta, GA. The role of DNMT3B in tumorigenesis.</i>
May 15, 2012	Seminar Speaker	<i>Stanford University, Division of Hematology, Palo Alto, CA The genetic and epigenetic landscape of myeloid malignancies.</i>
Feb 22, 2013	Seminar Speaker	<i>University of Michigan, Division of Hematology/Oncology, Ann Arbor, MI. The genetic and epigenetic landscape of hematopoietic malignancies.</i>
Mar 12, 2013	Seminar Speaker	<i>Ohio State University, Division of Hematology, Columbus, OH. The genetic and epigenetic landscape of hematopoietic malignancies.</i>

Mar 18, 2013	Seminar Speaker	<i>University of Puerto Rico, Rio Piedras. A Life in Medicine and Science.</i>
Mar 19, 2013	Seminar Speaker	<i>University of Puerto Rico, Humacao. Una vida en medicina y ciencia. Presented in Spanish</i>
Aug 20, 2013	Seminar Speaker	<i>Northwestern University, Lurie Children's Hospital Cancer Biology and Epigenomics Program, Chicago, IL. Defining the epigenetic landscape during normal and malignant hematopoiesis.</i>
Apr 23, 2014	Symposium Speaker	<i>Loyola University Stritch Medical School Epigenetics Symposium, Maywood, IL. Control of cell differentiation and phenotype by 5-hydroxymethylcytosine.</i>
Apr 25, 2014	Invited Speaker	<i>Agios Pharmaceuticals, Inc., Cambridge, MA. Control of cell differentiation and phenotype by 5-hydroxymethylcytosine.</i>
May 2, 2014	Seminar Speaker	<i>Yale Cancer Center, New Haven, CT. Control of cell differentiation and phenotype by 5-hydroxymethylcytosine.</i>
May 20, 2014	Seminar Speaker	<i>Control of cell differentiation and phenotype by 5-hydroxymethylcytosine. Presented at University of Massachusetts Medical School, Worcester, MA.</i>
Oct 17, 2014	Seminar Speaker	<i>University of IL at Chicago Department of Medicinal Chemistry and Pharmacology, o, Chicago, IL. Control of cell differentiation and phenotype by 5-hydroxymethylcytosine.</i>
Jan 17, 2015	Workshop Speaker	<i>7th Biennial Workshop on the Clinical Translation of Epigenetics in Cancer Therapy, St. Augustine, FL. HIF-1 directs the hypoxic response through TET1-mediated hydroxymethylation.</i>
Jan 21, 2015	Grand Rounds Speaker	<i>University of Minnesota, Department of Laboratory Medicine and Pathology, Minneapolis, MN. Control of cell differentiation and phenotype by 5-hydroxymethylcytosine.</i>
Feb 25, 2015	Grand Rounds Speaker	<i>University of Miami Sylvester Cancer Center, Hematology/Oncology Grand Rounds, Miami, FL. Control of cell differentiation and phenotype by 5-hydroxymethylcytosine.</i>
Mar 3, 2015	Seminar Speaker	<i>Albert Einstein College of Medicine, Developmental and Molecular Biology Seminar Series, Bronx, NY. Control of cell differentiation and phenotype by 5-hydroxymethylcytosine.</i>
Apr 13, 2015	Invited Speaker	<i>University of Texas Health Sciences Center San Antonio, San Antonio, TX. Bench to Bedside Seminar for MD/PhD students.</i>
Apr 14, 2015	Seminar Speaker	<i>University of Texas Health Sciences Center San Antonio, Molecular Biology Seminar Series, San Antonio, TX. Control of cell differentiation and phenotype by 5-hydroxymethylcytosine.</i>
Apr 24, 2015	Invited Speaker	<i>Leukemia and Lymphoma Society, Medical and Scientific Affairs Committee of the Boston, MA. Inherited predisposition to myeloid malignancies.</i>
May 12, 2015	Keynote Speaker	<i>Northwestern University, Chicago, IL. The 2015 Women's Forum on Physician-Scientists.</i>

Apr 4, 2016	Seminar Speaker	<i>Cold Spring Harbor Laboratories</i> , Defeating Cancer Seminar Series, Cold Spring Harbor, NY. Control of cancer cell phenotype by 5-hydroxymethylcytosine.
Jun 7, 2016	Invited Speaker	<i>Midwest Chromatin and Epigenetics Meeting</i> , Grand Rapids, MI. Control of cell differentiation and phenotype by 5-hydroxymethylcytosine.
Jun 22, 2016	Grand Rounds Speaker	<i>MD Anderson Cancer Center</i> , Emil J. Freireich Hematology Grand Rounds, Houston, TX. Defining the genetic and epigenetic changes that impact hematopoietic malignancies.
Sep 22, 2016	Seminar Speaker	<i>Roswell Park Cancer Institute</i> , Developmental Molecular and Genetics Seminar Series, Buffalo, NY. How 5-hydroxymethylcytosine regulates cancer cell phenotype.
Sep 23, 2016	Symposium Speaker	<i>Roswell Park Cancer Institute</i> , First Buffalo Niagara Medical Campus Translational Genomics and Epigenomics Symposium, Buffalo, NY. Control of cell differentiation by 5-hydroxymethylcytosine.
Oct 17, 2016	Invited Speaker	<i>Vanderbilt University</i> , Edward P. Evans Foundation MDS Research Summit, Nashville, TN. Using insights from hypoxia-induced changes in 5-hydroxymethylcytosine to improve MDS treatment.
Jan 14, 2017	Workshop Speaker	<i>8th Biennial Workshop on the Clinical Translation of Epigenetics in Cancer Therapy</i> , Jekyll Island, GA. Control of cell differentiation by 5-hydroxymethylcytosine and MYC.
Jan 27, 2017	Invited Speaker	<i>'Think Tank' on Integrating New Molecular Targets in Acute Leukemias</i> , Dallas, TX. Hereditary AML: Presentation and treatment challenges.
Aug 24, 2017.	Seminar Speaker	<i>Moffitt Cancer Center</i> , Tampa, FL. The role of germline mutations in the pathogenesis of hematopoietic malignancies.
Sep 13, 2017	Invited Speaker	<i>Department of Cell and Regenerative Biology, University of Wisconsin</i> , Madison, WI. Defining the genetic and epigenetic changes that impact hematopoietic malignancies.
Sep 27, 2017	Invited Speaker	<i>Center for Personalized Medicine, Children's Hospital of Los Angeles</i> . The role of germline genetic mutations in the development of hematopoietic malignancies.
Jan 26, 2018	Invited Speaker	<i>'Think Tank' on Integrating New Molecular Targets in Acute Leukemias</i> , Dallas, TX. Significance of germline mutations in acute leukemia.
Jan 27, 2018	Invited Speaker	<i>'Think Tank' on Integrating New Molecular Targets in Acute Leukemias</i> , Dallas, TX. RUNX1 mutation and leukemogenesis in AML.
Feb 6, 2018	Invited Speaker	<i>Gordon Research Conference on Oxygen Radicals</i> , Ventura, CA. The role of hypoxia in mediating epigenetic changes in pediatric neuroblastoma.
Feb 27, 2018	Invited Speaker	<i>Weill Cornell Medical College Hematology/Oncology Grand Rounds</i> , New York, NY. Germline predisposition to hematopoietic malignancies.

Jun 14, 2018	Invited Speaker	The Ohio State University Leukemia Research Program Seminar, Columbus, OH. Germline predisposition to hematopoietic malignancies.
Sep 14, 2018	Invited Speaker	<i>William Guy Forbeck Research Foundation Focus Meeting: "Metabolic Signaling"</i> , Lake Geneva, WI. TET gene regulation, the epigenome, and cancer risk.
Sep 28, 2018	Invited Speaker	<i>William Guy Forbeck Research Foundation Focus Meeting: "Epigenetic Therapy"</i> , Lake Geneva, WI. TET gene regulation, the epigenome, and cancer risk.
Nov 1, 2018	Plenary Speaker	<i>Association for Molecular Pathology 2018 Annual Meeting: Plenary Session, San Antonio, TX.</i> Inherited hematopoietic malignancies.
Jan 19, 2019	Workshop Speaker	<i>9th Biennial Workshop on the Clinical Translation of Epigenetics in Cancer Therapy</i> , Litchfield Park, AZ. TET gene regulation, the epigenome, and cancer risk.
Feb 7, 2019.	Invited Speaker	<i>Dana Farber Cancer Center Bone Marrow Transplant Grand Rounds, Boston, MA.</i> Inherited predisposition to hematopoietic malignancies.
Feb 13, 2019	Invited Speaker	<i>Simpson Querry Center for Epigenetics Lectureship, Northwestern University, Chicago, IL.</i> Regulation of cell differentiation by 5-hydroxymethylcytosine.
Apr 18, 2019	Invited Speaker	<i>Johns Hopkins School of Medicine Department of Molecular Biology and Genetics Seminar Series, Baltimore, MD.</i> Germline predisposition to hematopoietic malignancies.
Aug 2, 2019	Invited Speaker	<i>Yale Hematology Research Seminar Series, New Haven, CT.</i> Germline predisposition to hematopoietic malignancies.
Jan 22, 2020	Invited Speaker	<i>University of Washington Department of Laboratory Medicine Grand Rounds, Seattle, Washington.</i> Germline predisposition to hematopoietic malignancies.
Sept 21, 2020	Invited Speaker	<i>NIH, NIDDK Bioinformatic exploration of hematology cohort data, virtual webinar.</i> ClinGen-facilitated interactions.
Oct 16, 2020	Keynote Speaker	<i>Keith Minor Ford Memorial Lecture, University of Rochester Medical Center, Rochester, NY (virtual).</i> Discovering drivers of hematopoietic malignancies.

Clinical with regional attendees

May 2004	Grand Rounds Speaker	<i>Holy Cross Hospital, Hematology Grand Rounds, Chicago, IL.</i> Chronic myeloid leukemia.
Sep 2004	Grand Rounds Speaker	<i>University of Chicago, Department of Medicine Grand Rounds, Chicago, IL.</i> A rare leukemia reflects a common mechanism of human disease.
Aug 2007	Seminar Speaker	<i>University of Chicago, Chicago, IL.</i> Evaluating the role of truncated DNA methyltransferase 3B proteins in tumorigenesis.
Aug 17, 2007	Invited Speaker	<i>Joliet Oncology-Hematology Associates, Ltd., "Leukemia, Lymphoma, MDS, AML Cancer Awareness Program", Joliet, IL.</i> Novel targeted therapies for CML, ALL, and other hematologic malignancies.

Apr 17, 2008	Invited Speaker	<i>Leukemia and Lymphoma Society</i> , Chicago, IL. Learning more about leukemia, lymphoma, and multiple myeloma. Presented in Spanish.
Jul 11, 2009	Invited Speaker	<i>MDS Foundation Patient-Caregiver Forum</i> , Chicago, IL. New therapies and patient treatment options.
Sep 24, 2010	Seminar Speaker	<i>Emory University</i> , Section of Hematology/Oncology, Atlanta, GA. Risk stratification and treatment principles in AML.
Nov 10, 2010	Seminar Speaker	<i>University of Pennsylvania</i> , Section of Hematology/Oncology, Philadelphia, PA. Risk stratification and treatment principles in AML.
Nov 12, 2010	Invited Speaker	<i>Illinois Medical Oncology Society</i> annual meeting, Chicago, IL. Chronic myeloid leukemia: Paradigm for molecular targeting of cancer.
Feb 24, 2011	Seminar Speaker	<i>Evanston Hospital/NorthShore University Health System</i> , Evanston, IL. Identifying families with inherited leukemia syndromes.
May 24, 2011	CME Speaker	Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) Patient Monitoring, Dyer, IN.
Jun 5, 2011	CME Speaker	Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) Patient Monitoring, Chicago, IL.
Oct 24, 2011	CME Speaker	Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) Patient Monitoring, Chicago, IL.
Apr 20, 2012	Conference Speaker	<i>New Horizons in Cancer Genetics & Applications to Clinical Practice Conference</i> , Chicago, IL. New Frontiers: Genetics and Genetic Testing for Hematologic Malignancies.
Aug 7, 2012	Panelist	<i>Cancer Cytogenomics Microarray Consortium</i> Summer Meeting, Rosemont, IL.
Apr 20, 2013	Invited Speaker	<i>Leukemia and Lymphoma Society</i> , Oak Brook, IL. Cancer treatment: How to make informed choices about standard care and clinical trials.
May 2, 2013	Grand Rounds Speaker	<i>St. Jude Children's Research Hospital</i> , Leukemia/Lymphoma Grand Rounds, Memphis, TN. The legacy of leukemia: identifying familial predisposition to disease.
Nov 2, 2013	Invited Speaker	<i>National Association for Rare Diseases</i> , Pompano Beach, FL. Philadelphia Chromosome- myeloproliferative neoplasms.
Dec 17, 2013	Grand Rounds Speaker	<i>University of Chicago</i> Department of Medicine, Chicago, IL. Using the genetic and epigenetic landscape to understand disease.
Jan 31, 2014	Grand Rounds Speaker	<i>University of Illinois at Chicago</i> , Hematology/Oncology Grand Rounds, Chicago, IL. The legacy of leukemia: identifying familial predisposition to disease.
Jul 11, 2014	Grand Rounds Speaker	<i>Loyola University Medical Center</i> , Hematology/Oncology Grand Rounds, Maywood, IL. Identifying predisposition to hematopoietic malignancies.
Aug 12, 2014	Keynote Speaker	<i>Cancer Genomics Consortium and Cytogenomics Array Group</i> Summer Meeting, Chicago, IL. Control of cell differentiation and phenotype by 5-hydroxymethylcytosine.

Aug 16, 2014	Invited Speaker	<i>American Society of Clinical Oncology, Chicago Meeting, Chicago, IL. Review of Leukemia Abstracts.</i>
Sept 13, 2014	Invited Speaker	<i>Leukemia and Lymphoma Society and the Illinois Blood Cancer Conference, Chicago, IL. Conferencia del Cancer de la Sangre. Presented in Spanish.</i>
Mar 11, 2016	Grand Rounds Speaker	<i>Cleveland Clinic Grand Rounds, Cleveland, OH. Identifying inherited forms of hematopoietic malignancies.</i>
Apr 9, 2016	Invited Speaker	<i>Fifth Annual Clinical Cancer Genetics and Genomics Conference, Chicago, IL. Management of inherited hematologic malignancies.</i>
Apr 13, 2016	Seminar Speaker	<i>Michiana Hematology-Oncology/Saint Joseph Regional Medical Center, Mishawaka, IN. The molecular basis of inherited leukemia and lymphoma.</i>
Apr 13, 2016	Seminar Speaker	<i>Harper Cancer Research Institute, South Bend, IN. Identifying inherited hematopoietic malignancies.</i>
Apr 29, 2016	Seminar Speaker	<i>Roswell Park Cancer Center Grand Rounds, Buffalo, NY. Inherited predisposition to hematopoietic malignancies.</i>
Aug 3, 2017	Seminar Speaker	<i>Bone Marrow Transplant Educational Conference, University of CA, San Francisco, San Francisco, CA. The importance of germline mutations in hematologic malignancies and stem cell transplantation.</i>
Aug 5, 2017	Symposium Speaker	<i>V Foundation Wine Celebration Event, Napa Valley, CA. The genetics of blood cancers.</i>
Oct 7, 2017	Invited Panelist	<i>Leukemia and Lymphoma Society, Consulado Mexicano de Chicago. La lucha contra el cancer. Discussion held in Spanish.</i>
Mar 24, 2018	Invited Speaker	<i>Georgetown University CME Series on Bone Marrow Failure Syndromes, Tysons Corner, VA. Treatment of Secondary Acute Myeloid Leukemia.</i>
Sep 8, 2018	Invited Panelist	<i>Leukemia and Lymphoma Society, Consulado Mexicano de Chicago. Una conversación con expertos del canceres de sangre. Discussion held in Spanish.</i>
Sep 12, 2018	Invited Speaker/Chair	<i>Society of Hematologic Oncology Sixth Annual Meeting, Houston, TX. Chair and Debater: Should MDS Diagnosis still be mainly based on morphology? NO.</i>
Oct 5, 2019	Invited Panelist	<i>Leukemia and Lymphoma Society, Harrison Park Fieldhouse, Chicago, IL. Lo ultimo en el Cáncer de la Sangre. Discussion held in Spanish.</i>
Apr 17, 2020	Invited Speaker	<i>9th Annual International Clinical Cancer Genetics and Genomics Conference: Genetics in Clinical Cancer Care, Chicago, IL (virtual). Using NGS data from testing of leukemia/tumor cells to find germline mutations.</i>
Oct 9, 2020	Invited Speaker	<i>North American Pediatric Aplastic Anemia Consortium Virtual Scientific Symposium on Pediatric Bone Marrow Failure, Philadelphia, PA (virtual). Germline predisposition to MDS in young adults.</i>

PEER REVIEWED FUNDING

Current Funding

EvansMDS (Bresnick) 09/01/2020-08/31/2023

The Edward P. Evans Foundation

Building an Interpretive Guide to MDS-Linked Mutations from Patient Clinical Data

The goal of this project is to test GATA2 variants of uncertain significance that are identified from my patient population and test them functionally using Dr. Bresnick's *in vitro* complementation assays to define if they are likely pathogenic or benign.

Impact Award W81XWH1910241 (PI: Godley) 07/15/19-06/14/2022

Department of Defense

The impact of germline predisposition to myelodysplastic syndrome on allogeneic hematopoietic stem cell transplant outcomes using related donors

We will use paired samples from the Center for International Blood and Marrow Transplant Research to determine the frequency of germline mutations in acute leukemia and myelodysplastic syndrome (MDS) predisposing genes in patients with MDS and their Human Leukocyte Antigen (HLA)-matched related donors as well as to determine whether the presence of a germline variant, either in the recipient or the donor, influences engraftment kinetics and/or transplant outcomes.

Role: PI

U24 CA209996 (PI: Foster) 04/01/17-03/31/22

NIH/NCI

Building protected data sharing networks to advance cancer risk assessment and treatment

The extended Globus services will allow federation of clinical patient data for accurate cancer risk prediction, personalized treatment as well as any other cancer research area.

Role: Co-I

Bench-to-Bedside Administrative Supplement 03/01/19-02/28/21

Role: Co-PI

P20 CA233307-01 (PI: Olopade) 09/01/18 - 08/31/21

NIH

UChicago Interdisciplinary cancer health disparities SPORE

The goal is to facilitate translational research in Cancer Health Disparities by harnessing the intellectual capacity available at UChicago, Argonne National Laboratory and the City of Chicago.

Role: Co-Director of Pilot Projects

V Foundation for Cancer Research (PI: Godley) 11/01/17-10/31/20 NCE

Identifying inherited variants that predispose to lymphoid malignancies

The ultimate goal of using genetic risk factors to optimize therapy for patients and to develop preventive strategies to avoid cancer development in high-risk individuals.

Role: PI

The Searle Foundation and the Chicago Community Trust 01/01/17-12/31/21

The Chicago Biomedical Consortium

This grant supports the work of the Chicago Biomedical Consortium that unites the research efforts of The University of Chicago, Northwestern University, and the University of Illinois at Chicago to promote the health and well-being of Chicago citizens.

Role: Scientific Director for The University of Chicago

P30CA014599-41 (PI: Le Beau) 04/01/18-03/31/23

Cancer Center Support Grant

This is the cancer center support grant that supports The University of Chicago Comprehensive Cancer Center.

Role: Chair, Scientific Accrual and Monitoring Committee within the Protocol Review and Monitoring System

*In addition to the grants listed above, Dr. Godley is involved in clinical trials at the University of Chicago. She has evaluated her clinical study obligations and confirms that the aggregated effort on all trials listed below does not exceed 0.3 Calendar Months.

Past Support

Leukemia and Lymphoma Society Translational Research Program Award (PI: Godley)	10/01/16-09/30/19
"Modeling myeloid malignancies mediated by germline <i>RUNX1</i> , <i>ETV6</i> , and <i>ANKRD26</i> mutations"	
Cancer Research Award Fletcher Award (PI: Godley)	07/01/16-06/30/19
" <i>CHEK2</i> mutations as predisposition alleles for inherited hematopoietic malignancies"	
Edward P. Evans Foundation (PI: Godley/Wickrema)	09/01/15-08/31/18
"Using insights from hypoxia-induced changes in 5-hydroxymethylcytosine to improve MDS treatment"	
Taub Foundation (PI: Godley)	11/01/15-10/31/18
"Identification of Germline Predisposition Syndromes in Young MDS Patients"	
NIH R21 HG006367 (PI: Zhang, Godley, Dolan)	06/01/12-05/31/15
"Epigenetic and Genetic Dissection of Drug Response"	
National Institutes of Health R21 CA156139-01 (PI: Sohn, subcontract- Godley)	12/01/10 - 07/31/13
"Rapid Label-Free Detection of Acute Promyelocytic Leukemia"	
National Institutes of Health/NCI R01 CA129831 (PI: L.A. Godley)	04/01/08-03/31/13
"The Role of DNMT3B in the DNA Methylation of Cancer Cells"	
3R01 CA129831-03S1 (PI: L.A. Godley)	
"Defining the genomic distribution of 5-hydroxymethylcytosine"	
National Institutes of Health R21 CA138310 (PI: L.A. Godley)	04/01/08-03/31/11
"A chemical crosslinking strategy to determine DNA methylating protein complexes"	
Department of Defense ARO (PI: J. Fackenthal, Co-PI: L.A. Godley)	07/01/07- 07/31/10
"A functional assay for allele-specific BRCA1/2 mRNA null phenotypes in breast/ovarian cancer families"	
National Science Foundation (PI: L. Sohn, Co-PI: L.A. Godley)	06/01/07-05/31/10
"NanoCytometry: A point-of-care technology"	
Cancer Research Foundation	01/01/04-12/31/04
"Deciphering the molecular basis for the DNA methylation patterns in cancer cells"	
The Schweppe Foundation	04/01/04-03/31/06
"Deciphering the mechanism of abnormal DNA methylation in cancer cells"	
The Sidney Kimmel Foundation	07/01/05-06/30/07
"Role of DNMT3B in mediating the abnormal DNA methylation patterns in cancer cells"	
American Cancer Society, IL Division	01/01/08-12/30/08
"DNMT3B and the abnormal DNA methylation of cancer cells"	
National Institutes of Health R21 HG006367 (PI: Zhang, Godley, Dolan)	06/01/12-05/31/15
"Epigenetic and Genetic Dissection of Drug Response"	
Cancer Research Foundation (PI: Godley)	01/01/15-12/31/16
Identifying germline mutations in young patients with myelodysplastic syndromes	
Wells Fargo- Anna Fuller Trust Fund (PI: Godley)	04/01/15-03/31/17
Epigenetic control of hematopoietic stem cell function	

Past Support- Clinical/Translational

Onconova Therapeutics, Inc.	03/10/11-06/30/14
"A Phase III Multicenter, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine."	
MGI Pharma	07/26/05-06/30/08
"DACO-020: Alternative dosing for outPatient treatment (ADOPT)"	

Cephalon	07/30/05-12/31/10
“C0701a/204/ON/US: Oral CEP-701 administered in sequence with standard chemotherapy to patients with relapsed or acute myeloid leukemia (AML) Expressing FLT-3 activating mutations”	
Genzyme	
Pharmion/Celgene	03/21/07-03/20/11
“Correlative studies to accompany 5-azacytidine/PDX101 clinical trial for patients with refractory hematologic malignancies”	
Eisai Inc.	04/27/09-04/26/11
“DACO-026: A randomized open-label Phase 2 study of low dose Dacogen for injection (Decitabine) in patients with low or intermediate-1 risk myelodysplastic syndromes”	
Eisai, Inc.	11/02/10-02/01/11
“A randomized, open label, parallel group study comparing the efficacy and safety of DACOGEN (decitabine) for injection and VIDAZA (azacitidine) for injection in subjects with intermediate or high risk myelodysplastic syndromes (MDS).”	

PUBLICATIONS

Peer-Reviewed Publications

1. **Godley, L.A.**, Pfeifer, J., Steinhauer, D., Ely, B., Shaw, G., Kaufmann, R., Suchanek, E., Pabo, C., Skehel, J.J., and Wiley, D.C. Introduction of intersubunit disulfide bonds in the membrane-distal region of the influenza hemagglutinin abolishes membrane fusion activity. *Cell* 68: 635-645 (1992).
2. Varmus, H.E., **Godley, L.A.**, Roy, S., Taylor, I.C.A., Yuschenkoff, L., Shi, Y.-P., Pinkel, D., Gray, J., Pyle, R., Aldaz, C.M., Bradley, A., Medina, D., and Donehower, L.A. Defining the steps in a multistep mouse model for mammary carcinogenesis. *Cold Spring Harb Symp Quant Biol*. Volume LIX, 491-499 (1994).
3. Donehower, L.A., **Godley, L.A.**, Aldaz, C.M., Pyle, R., Shi, Y.-P., Pinkel, D., Gray, J., Bradley, A., Medina, D., and Varmus, H.E. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. *Genes Dev*. 9: 882-895 (1995).
4. Donehower, L.A., **Godley, L.A.**, Aldaz, C.M., Pyle, R., Shi, Y.-P., Pinkel, D., Gray, J., Bradley, A., Medina, D., and Varmus, H.E. The role of p53 loss in genomic instability and tumor progression in a murine mammary cancer model. *Prog. Clin. Biol. Res*. 395: 1-11 (1996).
5. **Godley, L.A.**, Kopp, J.B., Eckhaus, M., Paglino, J.J., Owens, J., and Varmus, H.E. Wild-type p53 transgenic mice exhibit altered differentiation of the ureteric bud and possess small kidneys. *Genes Dev*. 10: 836-850 (1996).
6. Broccoli, D., **Godley, L.A.**, Donehower, L.A., Varmus, H.E., and de Lange, T. Telomerase activation in mouse mammary tumors: Lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation. *Mol. Cell. Biol*. 16: 3765-3772 (1996).
7. Jones, J.M., Attardi, L., **Godley, L.A.**, Laucirica, R., Medina, D., Jacks, T., Varmus, H.E., and Donehower, L.A. Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis. *Cell Growth and Diff*. 8: 829-838 (1997).
8. **Godley, L.A.**, Lai, F., Liu, J., Zhao, N., and Le Beau, M.M. TTID: A novel gene at 5q31 encoding a protein with titin-like features. *Genomics*. 60: 226-233 (1999).
9. Lai, F., Orelli, B.J., Till, B.G., **Godley, L.A.**, Fernald, A.A., Pamintuan, L., and Le Beau, M.M. Molecular characterization of *KLHL3*, a human homologue of the *Drosophila kelch* gene. *Genomics*. 66: 65-75 (2000).

10. Lai, F., **Godley, L.A.**, Fernald, A.A., Orelli, B.J., Pamintuan, L., Zhao, N., and Le Beau, M.M. cDNA cloning and genomic structure of three genes localized to human chromosome band 5q31 encoding novel nuclear proteins. *Genomics*. 70: 123-130 (2000).
11. Lai, F., **Godley, L.A.**, Joslin, J., Fernald, A.A., Liu, J., Espinosa III, R., Zhao, N., Pamintuan, L., Till, B.G., Larson, R.A., Qian, Z., and Le Beau, M.M. Transcript map and comparative analysis of the 1.5 Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). *Genomics*. 71: 235-245 (2001).
12. Qian, Z., Fernald, A.A., **Godley, L.A.**, Larson, R.A., and Le Beau, M.M. Expression profiling of CD34+ hematopoietic stem/progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. *Proc. Natl. Acad. Sci. USA*, 99: 14925-14930 (2002).
13. van Besien, K., Artz, A., Smith, S., Cao, D., Rich, S., **Godley, L.**, Jones, D., Del Cerro, P., Bennett, D., Casey, B., Odenike, O., Thirman, M., Daugherty, C., Wickrema, A., Zimmerman, T., Larson, R.A., and Stock, W. Fludarabine, melphalan, and alemtuzumab conditioning in adults with advanced acute myeloid leukemia and myelodysplastic syndrome: excellent outcomes in patients with standard-risk disease. *J. Clin. Oncol.* 23: 5728-5738 (2005).
14. Kline, J., Pollyea, D.A., Stock, W., Artz, A., Rich, E., **Godley, L.**, Zimmerman, T., Thompson, K., Pursell, K., Larson, R.A., and van Besien, K. Pre-transplant Ganciclovir and post-transplant high-dose valacyclovir reduce CMV infections after alemtuzumab based conditioning. *Bone Marrow Transpl.*, 37(3): 307-310 (2006).
15. Artz, A., Pollyea, D.A., Kocherginsky, M., Stock, W., Rich, E., Odenike, O., Zimmerman, T., Smith, S., **Godley, L.**, Thirman, M., Daugherty, C., Extermann, M., Larson, R., and van Besien, K. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. *Biol Bone Marrow Transplant* 12: 954-964 (2006).
16. Ostler, K.R., Davis, E.M., Payne, S.L., Patel, B.B., Exposito-Cespedes, J., Le Beau, M.M., and **Godley, L.A.** Cancer cells express aberrant DNMT3B transcripts encoding truncated proteins. *Oncogene* 26: 5553-5563 (2007).
17. Pollyea, D.A., Artz, A.S., Stock, W., Daugherty, C., **Godley, L.**, Odenike, O.M., Rich, E., Smith, S.M., Zimmerman, T., Zhang, Y., Huo, D., Larson, R., and van Besien, K. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant.* 40: 1027-1032 (2007).
18. Hill, B.T., Kondapalli, L., Artz, A., Smith, S.M., Rich, E., **Godley, L.**, Odenike, O., Pursell, K.J., Larson, R.A., Stock, W., and van Besien, K. Successful allogeneic transplantation of patients with suspected prior invasive mold infection. *Leuk Lymphoma* 48: 1799-1805 (2007).
19. Gordon, M.K., Sher, D., Karrison, T., Kebriaei, P., Chuang, K., Zhang, Y., McDonnell, D., Artz, A., **Godley, L.**, Odenike, O., Rich, E., Michaelis, L., Thirman, M.J., Wickrema, A., van Besien, K., Larson, R.A., and Stock, W. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow and apheresis products. *Leuk Lymphoma* 49: 531-537 (2008).
20. Klisovic, R.B., Stock, W., Cataland, S., Klisovic, M.I., Liu, S., Blum, W., Green, M., Odenike, O., **Godley, L.**, Burgt, J.V., Van Laar, E., Cullen, M., Macleod, A.R., Besterman, J.M., Reid, G.K., Byrd, J.C., and Marcucci, G. A phase I biological study of MG98, an oligodeoxynucleotide

antisense to DNA methyltransferases 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. *Clin Cancer Res* 14(8): 2444-2449 (2008).

21. Stock, W., Undevia, S.D., Bivins, C., Ravandi, F., Odenike, O., Faderl, S., Rich, E., Borthakur, G., **Godley, L.**, Verstovsek, S., Artz, A., Wierda, W., Larson, R.A., Zhang, Y., Cortes, J., Ratain, M.J., and Giles, F.J. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. *Invest New Drugs* 26: 331-338 (2008).
22. Ozer, O., Zhao, Y.D., Ostler, K.R., Akin, C., Anastasi, J., Vardiman, J.W., and **Godley, L.A.** The identification and characterization of novel *KIT* transcripts in aggressive mast cell malignancies and normal CD34+ cells. *Leuk Lymphoma* 49: 1567-1577 (2008).
23. Carbonaro, A., Mohanty, S.K., Huang, H., **Godley, L.A.**, and Sohn, L.L. NanoCytometry: A label-free technique for performing single-cell screening. *Lab Chip* 8: 1478-1485 (2008).
24. Artz, A.S., Wickrema, A., Dinner, S., **Godley, L.A.**, Kocherginsky, M., Odenike, O., Rich, E.S., Stock, W., Ulaszek, J., Larson, R.A., and van Besien, K. Pre-treatment C-reactive protein (CRP) is a predictor for outcomes after reduced intensity allogeneic hematopoietic cell transplantation. *Biol Bone Marrow Transpl.* 14: 1209-1216 (2008).
25. Poiré, X., Artz, A., Larson, R.A., Kline, J., Odenike, O., Rich, E., **Godley, L.**, Stock, W., van Besien, K. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. *Leuk Lymphoma* 50: 85-91 (2009).
26. Zhou, Y., Goodenbour, J.M., **Godley, L.A.**, Wickrema, A., and Pan, T. High levels of tRNA abundance and alteration of tRNA charging by bortezomib in multiple myeloma. *Biochem Biophys. Res. Comm.* 385: 160-164 (2009).
27. Steensma, D.P., Baer, M., Slack, J., Buckstein, R., **Godley, L.A.**, Garcia-Manero, G., Albitar, M., Larsen, J.S., Arora, S., Cullen, M., and Kantarjian, H.M. Multi-center study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: The ADOPT (alternative dosing for outpatient treatment) Trial. *J Clin. Oncol.* 27: 3842-3848 (2009).
28. van Besien, K., Dew, A., Lin, S., Joseph, L., **Godley, L.A.**, Larson, R.A., Odenike, O., Rich, E., Stock, W., Wickrema, A., and Artz, A. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. *Leuk Lymphoma* 50: 1809-1817 (2009).
29. **Godley, L.A.**, Njiaju, U.O., Green, M., Weiner, H., Lin, S., Odenike, O., Stock, W., Rich, E.S., Artz, A., van Besien, K., Daugherty, C.K., White, C., Ridgeway, J., Zhang, Y., Le Beau, M.M., and Larson, R.A., Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplantation. *Leuk Lymphoma* 51: 995-1006 (2010).
30. Shah, M.Y., Vasanthakumar, A., Barnes, N.Y., Figueroa, M.E., Kamp, A., Hendrick, C., Ostler, K.R., Davis, E.M., Lin, S., Anastasi, J., Le Beau, M.M., Moskowitz, I., Melnick, A., Pytel, P., and **Godley, L.A.** DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis. *Cancer Research* 70: 5840-5850 (2010).

31. Yang, Q., Tian, Y., Ostler, K.R., Chlenski, A., Guerrero, L., Salwen, H.R., **Godley, L.A.**, and Cohn, S.L. Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines. *BioMed Central Cancer* 10: 286-296 (2010).
32. Churpek, J.E., Garcia, J.S., Madzo, J., Jackson, S., Onel, K., and **Godley, L.A.** Identification and molecular characterization of a novel 3' mutation in *RUNX1* in a family with Familial Platelet Disorder. *Leuk Lymphoma* 51: 1931-1935 (2010).
33. Figueroa, M.E., Abdel-Wahab, O., Lu, C., Ward, P.S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H.F., Tallman, M.S., Sun, Z., Wolniak, K., Peeters, J.K., Liu, W., Choe, S.E., Fantin, V.R., Paietta, E., Lowenberg, B., Licht, J.D., **Godley, L.A.**, Delwel, R., Valk, P.J.M., Thompson, C.B., Levine, R.L., and Melnick, A. IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer Cell* 18: 553-567 (2010).
34. O'Donnell, P.H., Artz, A.S., Undevia, S.D., Pai, R.K., del Cerro, P., Horowitz, S. **Godley, L.A.**, Hart, J., Innocenti, F., Larson, R.A., Odenike, O.M., Stock, W., and van Besien, K. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplantation. Reduced clearance at high doses and occurrence of late SOS/VOD. *Leuk Lymphoma* 51: 2240-2249 (2010).
35. Song, C.-X., Szulwach, K.E., Fu, Y., Dai, Q., Yi, C., Li, X., Chen, C.-H., Zhang, W., Jian, X., Wang, J., Zhang, L., Looney, T.J., Zhang, B., **Godley, L.A.**, Hicks, L.M., Lahn, B.T., and He, C. Selective labeling of 5-hydroxymethylcytosine in genomic DNA from cell lines and murine tissues. *Nature Biotech* 29: 68-72 (2011).
36. Kenkre, V.P., Horowitz, S., Artz, A.S., Liao, C., Cohen, K.S., **Godley, L.A.**, Kline, J.P., Smith, S.M., Stock, W., van Besien, K. Alemtuzumab-containing conditioning for allogeneic transplant (HCT) in lymphoma: Predictors of outcome. *Leuk Lymphoma* 52: 214-222 (2011).
37. Levis, M., Ravandi, F., Wang, E.S., Baer, M.R., Perl, A., Coutre, S., Erba, H., Stuart, R.K., Baccarani, M., Cripe, L.D., Tallman, M.S., Meloni, G., **Godley, L.A.**, Langston, A.A., Amadori, S., Lewis, I.D., Nagler, A., Stone, R., Yee, K., Advani, A., Douer, D., Jedrzejczak, W.W., Juliusson, G., Litzow, M.R., Petersdorf, S., Sanz, M., Kantarjian, H.M., Sato, T., Tremmel, L., Bensen-Kennedy, D.M., Small, D., and Smith, B.D. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. *Blood* 117: 3294-3301 (2011).
38. Woloszynska-Read, A., Zhang, W., Yu, J., Link, P.A., Mhawech-Fauceglia, P., Collamat, G., Akers, S.N., Ostler, K.R., **Godley, L.A.**, Odunsi, K., and Karpf, A.R. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with *BORIS/CTCF* mRNA expression ratio. *Clin Cancer Res* 17: 2170-2180 (2011).
39. Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M.E., Vasanthakumar, A., Patel, J., Zhao, X., Perna, F., Pandey, S., Madzo, J., Song, C., Dai, Q., He, C., Ibrahim, S., Beran, M., Zavadil, J., Nimer, S., Melnick, A., **Godley, L. A.**, Aifantis, I., and Levine, R. L. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. *Cancer Cell* 20: 11-24 (2011).
40. Quivoron, C., Couronné, L., Della Valle, Véronique, Lopez, C., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.-H., **Godley, L.**, Opolon, P., Tilly, H., Solary, E., Duffourd, Y., Dessen, P., Merle-Beral, H., Nguyen-Khac, F., Fontenay, M., Vainchenker, W., Bastard, C., Mercher, T., and Bernard, O. A. TET2 inactivation results in pleiotropic

hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. *Cancer Cell* 20: 25-38 (2011).

41. Pronier, E., Almire, C., Mokrani, H., Vasanthakumar, A., Simon, A., da Costa Reis Monte Mor, B., Masse, A., Le Couedic, J.-P., Pendino, F., Carbonne, B., Larghero, J., Ravanat, J.-L., Casadevall, N., Bernard, O.A., Droin, N., Solary, E., **Godley, L.A.**, Vainchenker, W., Plo, I., and Delhommeau, F. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulo-monocytic differentiation of human hematopoietic progenitors. *Blood* 118: 2551-2555 (2011).
42. Shaknovich, R., Cerchietti, L., Tsikitas, L., Kormaksson, M., De, S., Figueroa, M.E., Ballon, G., Yang, S.N., Weinhold, N., Reimers, M., Clozel, T., Luttrup, K., Ekstrom, T.J., Frank, J., Vasanthakumar, A., **Godley, L.A.**, Michor, F., Elemento, O., and Melnick, A. DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. *Blood* 118: 3559-3569 (2011).
43. Liu, H., Rich, E.S., **Godley, L.**, Odenike, O., Joseph, L., Marino, S., Kline, J., Nguyen, V., Cunningham, J., Larson, R.A., del Cerro, P., Schroeder, L., Pape, L., Stock, W., Wickrema, A., Artz, A.S., and van Besien, K. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. *Blood* 118: 6438-6445 (2011).
44. Szulwach, K.E., Li, X., Li, Y., Song, C.-X., Wu, H., Dai, Q., Irier, H., Upadhyay, A.K., Gearing, M., Levey, A.I., Vasanthakumar, A., **Godley, L.A.**, Chang, Q., Cheng, X., He, C., and Jin, P. 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. *Nat Neurosci* 14: 1607-1616 (2011).
45. Challen, G.A., Sun, D., Jeong, M., Luo, M., Jelinek, J., Berg, J.S., Bock, C., Vasanthakumar, A., Gu, H., Xi, Y., Liang, S., Lu, Y., Darlington, G.J., Meissner, A., Issa, J.-P. J., **Godley, L.A.**, Li, W., and Goodell, M.A. Dnmt3a is essential for hematopoietic stem cell differentiation. *Nature Genetics* 44: 23-31 (2011).
46. van Besien, K., Stock, W., Rich, E., Odenike, O., **Godley, L.**, O'Donnell, P.H., Kline, J., Nguyen, V., Larson, R., and Artz, A. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. *Biol Bone Marrow Transpl.* 18: 913-921 (2012).
47. Doçi, C.L., Mankame, T.P., Langerman, A., Ostler, K.R., Kanteti, R., Best, T., Onel, K., **Godley, L.A.**, Salgia, R., and Lingen, M.W. Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer. *Int J Gynecol Pathol* 31:15-24 (2012).
48. Larson, S.M., Campbell, N.P., Huo, D., Artz, A., Zhang, Y., Gajria, D., Green, M., Weiner, H., Daugherty, C., Odenike, O., **Godley, L.A.**, Hyjek, E., Gurbuxani, S., Thirman, M., Sipkins, D., van Besien, K., Larson, R.A., and Stock, W. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). *Leuk Lymphoma* 53: 445-450 (2012).
49. Yamazaki, J., Taby, R., Vasanthakumar, A., Macrae, T., Ostler, K.R., Shen, L., Kantarjian, H.M., Estecio, M.R., Jelinek, J., **Godley, L.A.**, and Issa, J.-P.J. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. *Epigenetics* 7: 201-207 (2012).
50. Nanduri, J., Makarenko, V., Reddy, V.D., Yuan, G., Pawar, A., Wang, N., Khan, S.A., Zhang, X., Kinsman, B., Peng, Y.J., Kumar, G.K., Fox, A.P., **Godley, L.A.**, Semenza, G.L., and Prabhakar,

- N.R. Epigenetic regulation of hypoxic sensing disrupts cardiorespiratory homeostasis. *Proc Natl Acad Sci USA* 109: 2515-2520 (2012).
51. Richa, E.M., Kunnavakkam, R., **Godley, L.A.**, Kline, J., Odenike, O., Larson, R.A., Nguyen, V., Stock, W., Wickrema, A., van Besien, K., Artz, A. Influence of related donor age on outcomes after peripheral blood stem cell transplantation. *Cytotherapy* 14: 707-715 (2012).
52. Ostler, K.R., Yang, Q., Looney, T.J., Zhang, L., Vasanthakumar, A., Tian, Y., Kocherginsky, M., Raimondi, S.L., DeMaio, J.G., Salwen, H.R., Gu, S., Chlenski, A., Naranjo, A., Gill, A., Peddinti, R., Lahn, B.T., Cohn, S.L., and **Godley, L.A.** Truncated DNMT3B isoform DNMT3B7 suppresses growth, induces differentiation, and alters DNA methylation in human neuroblastoma. *Cancer Research* 72: 4714-4723 (2012).
53. Busque, L., Patel, J.P., Figueroa, M., Vasanthakumar, A., Provost, S., Hamilou, Z., Mollica, L., Li, J., Viale, A., Heguy, A., Hassimi, M., Socci, N., Bhatt, P.K., Gonen, M., Mason, C.E., Melnick, A., **Godley, L.A.**, Brennan, C., Abdel-Wahab, O., and Levine, R.L. Recurrent somatic *TET2* mutations in normal elderly individuals with clonal hematopoiesis. *Nature Genetics* 44: 1179-1181 (2012).
54. Churpek, J.E., Nickels, E., Marquez, R., Rojek, K., Liu, B., Lorenz, R., Lepore, J., Madzo, J., Wickrema, A., Artz, A., van Besien, K., and **Godley, L.A.** Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplant donors with thrombocytopenia. *Blood* 120: 5247-5249 (2012).
55. Churpek, J.E., Lorenz, R., Nedumgottil, S., Onel, K., Olopade, O., Sorrell, A., Owen, C.J., Bertuch, A.A., and **Godley, L.A.** A proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes. *Leuk Lymphoma* 54: 28-35 (2013).
56. Pollyea, D.A., Kohrt, H.E., Zhang, B., Zehnder, J., Schenkein, D., Fantin, V., Straley, K., Vasanthakumar, A., Abdel-Wahab, O., Levine, R., **Godley, L.A.**, and Medeiros, B.C. 2-Hydroxyglutarate in IDH mutant AML: Predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. *Leuk Lymphoma* 54: 408-410 (2013).
57. Vasanthakumar, A., Lepore, J.B., Zegarek, M.H., Kocherginsky, M., Singh, M., Davis, E.M., Link, P.A., Anastasi, J., Le Beau, M.M., Karpf, A.R., and **Godley, L.A.** Dnmt3b is a haploinsufficient tumor suppressor gene in *Myc*-induced lymphomagenesis. *Blood* 121: 2059-2063 (2013).
58. Yu, Y., Mo, Y., Ebenezer, D., Bhattacharyya, S., Liu, H., Sundaravel, S., Wonkatal, S., Cartier, J., Caces, B., Artz, A., Nischal, S., Bhagat, T., Bathon, K., Maqbool, S., Gligich, O., Suzuki, M., Steidl, U., **Godley, L.**, Skoultschi, A., Grealley, J., Wickrema, A., and Verma, A. High resolution methylome analysis reveals widespread functional hypomethylation during adult human erythropoiesis. *J Biol Chem.* 288: 8805-8814 (2013).
59. Lu, Z., Tian, Y., Salwen, H.R., Chlenski, A., **Godley, L.A.**, Raj, J.U., and Yang, Q. Histone lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells. *Anti-Cancer Drugs* 24: 484-493 (2013).
60. Jain, N., Artz, A., Anastasi, J., Odenike, O., **Godley, L.A.**, Joseph, L., Marino, S., Kline, J., Nguyen, V., Schouten, V., Kunnavakkam, R., Larson, R.A., Stock, W., Ulaszek, J., Savage, P.A., Wickrema, A., and van Besien, K. Immune reconstitution after combined haploidentical and umbilical cord blood transplant. *Leuk Lymphoma* 54: 1242-1249 (2013).

61. Garcia-Manero, G., Jabbour, E., Borthakur, G., Faderl, S., Estrov, Z., Yang, H., Maddipoti, S., **Godley, L.A.**, Gabrail, N., Berdeja, J.G., Nadeem, A., Kassalow, L., and Kantarjian, H. Randomized open-label Phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. *J. Clin. Oncol.* 31: 2548-2553 (2013).
62. Locke, F., Agarwal, R., Kunnavakkam, R., van Besien, K., Larson, R.A., Odenike, O., **Godley, L.A.**, Liu, H., Le Beau, M.M., Gurbuxani, S., Thirman, M.J., Sipkins, D., White, C., Artz, A., Stock, W. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. *Bone Marrow Transplant.* 48: 1437-1443 (2013).
63. Moen, E.L., Zhang, X., Mu, W., Delaney, S.M., Wing, C., McQuade, J., Myers, J., **Godley, L.A.**, Dolan, M.E., and Zhang, W. Genome-wide variation of cytosine modifications between European and African populations and the implications for complex traits. *Genetics* 194: 987-996 (2013).
64. Clozel, T., Yang, S., Elstrom, R., Tam, W., Kormaksson, M., Banerjee, S., Vasanthakumar, A., Culjkovic, B., Scott, D., Ammerpohl, O., Brennan, S., Leser, M., Martin, P., Borden, K., Shaknovich, R., Siebert, R., Chadburn, A., **Godley, L.A.**, Gascoyne, R., Leonard, J.P., Melnick, A., and Cerchietti, L. SMAD1 demethylation contributes to epigenetic chemosensitization of human diffuse large B cell lymphoma *Cancer Discov* 3: 1-18 (2013).
65. Bhattacharyya, S., Yu, Y., Suzuki, M., Campbell, N., Mazdo, J., Vasanthakumar, A., Bhagat, T.D., Nischal, S., Christopheit, M., Parekh, S., Steidl, U., **Godley, L.**, Maitra, A., Grealley, J.M., and Verma, A. Genome-wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer. *Nucl. Acids Res.* 41: e157 (2013).
66. Jeong, M., Sun, D., Luo, M., Huang, Y., Challen, G.A., Rodriguez, B., Zhang, X., Chavez, L., Wang, H., Hannah, R., Kim, S.B., Yang, L., Ko, M., Chen, R., Göttgens, B., Lee, J.S., Gunaratne, P., **Godley, L.A.**, Darlington, G.J., Rao, A., Li, W., and Goodell, M.A. Large conserved domains of low DNA methylation maintained by Dnmt3a. *Nature Genetics* 46: 17-23 (2014).
67. Madzo, J., Liu, H., Rodriguez, A., Vasanthakumar, A., Sundaravel, S., Caces, D.B., Looney, T.J., Zhang, L., Lepore, J.B., Macrae, T., Duszynski, R., Shih, A.H., Song, C.X., Yu, M., Yu, Y., Grossman, R., Raumann, B., Verma, A., He, C., Levine, R.L., Lavelle, D., Lahn, B.T., Wickrema, A., and **Godley, L.A.** Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis. *Cell Rep.* 6: 231-244 (2014).
68. Chambwe, N., Kormaksson, M., Geng, H., De, S., Michor, F., Johnson, N.A., Morin, R.D., Scott, D.W., **Godley, L.A.**, Gascoyne, R.D., Melnick, A., Campagne, F., and Shaknovich, R. Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. *Blood* 123: 1699-1708 (2014).
69. Moen, E.L., Stark, A.L., Zhang, W., Dolan, M.E., and **Godley, L.A.** The role of gene body cytosine modifications in *MGMT* expression and sensitivity to temozolomide. *Mol Cancer Ther.* 13: 1334-1344 (2014).
70. Mariani, C.J., Vasanthakumar, A., Madzo, J., Yesilkanal, A., Bhagat, T., Yu, Y., Bhattacharyya, S., Wenger, R.H., Cohn, S.L., Nanduri, J., Verma, A., Prabhakar, N.R., and **Godley, L.A.** TET1-mediated hydroxymethylation facilitates hypoxic gene induction in neuroblastoma. *Cell Rep.* 7:1343-52 (2014).

71. Muffly, L.S., Kocherginsky, M., Stock, W., Chu, Q., Bishop, M.R., **Godley, L.A.**, Kline, J., Liu, H., Odenike, O.M., Larson, R.A., van Besien, K., and Artz, A.S. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. *Haematologica* 99: 1373-1379 (2014).
72. Ustun, C., Reiter, A., Scott, B.L., Nakamura, R., Damaj, G., Kreil, S., Shanley, R., Hogan, W.J., Perales, M.A., Shore, T., Baumann, H., Stuart, R., Gruhn, B., Doubek, M., Hsu, J.W., Tholouli, E., Gromke, T., **Godley, L.A.**, Pagano, L., Gilman, A., Wagner, E.M., Shwayder, T., Bornhäuser, M., Papadopoulos, E.B., Böhm, A., Vercellotti, G., Van Lint, M.T., Schmid, C., Rabitsch, W., Pullarkat, V., Legrand, F., Yakoub-Agha, I., Saber, W., Barrett, J., Hermine, O., Hagglund, H., Sperr, W.R., Popat, U., Alyea, E.P., Devine, S., Deeg, H.J., Weisdorf, D., Akin, C., and Valent, P. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. *J Clin. Oncol.* 32: 3264-3274 (2014).
73. Zhang, X., Moen, E.L., Mu, W., Gamazon, E.R., Delaney, S.M., Wing, C., **Godley, L.A.**, Dolan, M.E., and Zhang, W. Linking the genetic architecture of cytosine modifications with human complex traits. *Human Molec Genet.* 23: 5893-5905 (2014).
74. Marquez, R., Hantel, A., Lorenz, R., Neistadt, B., Wong, J., Churpek, J.E., Al Mardini, N., Shaukat, I., Gurbuxani, S., Miller, J., and **Godley, L.A.** A new family with a germline *ANKRD26* mutation and predisposition to myeloid malignancies. *Leuk Lymphoma* 55: 2945-2946 (2014).
75. Rampal, R., Alkalin, A., Madzo, J., Vasanthakumar, A., Patel, J., Li, Y., Ahn, J., Abdel-Wahab, O., Shih, A., Lu, C., Ward, P.S., Tsai, J.J., Hricik, T., Tosello, V., Tallman, J.E., Zhao, X., Daniels, D., Dai, Q., Ciminio, L., Aifantis, I., He, C., Fuks, F., Tallman, M.S., Ferrando, A., Carroll, M., Paietta, E., Thompson, C.B., Licht, J.D., Mason, C., **Godley, L.A.**, Melnick, A., Figueroa, M.E., and Levine, R.L. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. *Cell Rep.* 9: 1841-1855 (2014).
76. Zhang, M.Y., Churpek, J.E., Keel, S.B., Walsh, T., Lee, M.K., Loeb, K.R., Gulsuner, S., Pritchard, C.C., Sanchez-Bonilla, M., Delrow, J.J., Basom, R.S., Forouhar, M., Gyurkocza, B., Schwartz, B.S., Neistadt, B., Marquez, R., Mariani, C., Coats, S., Hofmann, I., Lindsley, R.C., Williams, D.A., Abkowitz, J.L., Horwitz, M.S., King, M.-C., **Godley, L.A.**, and Shimamura, A. Germline *ETV6* mutations in familial thrombocytopenia and hematologic malignancy. *Nature Genetics* 47: 180-185 (2015).
77. Odenike, O., Halpern, A., **Godley, L.A.**, Mado, J., Karrison, T., Green, M., Fulton, N., Mattison, R.J., Yee, K.W., Bennett, M., Koval, G., Malnassy, G., Larson, R.A., Ratain, M.J., and Stick, W. A phase I and pharmacodynamics study of the histone deacetylase inhibitor belinostat plus Azacitidine in advanced myeloid neoplasia. *Invest New Drugs* 33: 371-379 (2015).
78. Brambert, P.R., Kelsch, D.J., Hameed, R., Desai, C.V., Calafiore, G., **Godley, L.A.**, and Raimondi, S.L. DNMT3B7 expression promotes tumor progression to a more aggressive phenotype in breast cancer cells. *PLoS One.* 10: e0117310 (2015).
79. Balakrishnan, K.R., Whang, J.C., Hwang, R., Hack, J.H., **Godley, L.A.**, and Sohn, L.L. Node-pore sensing enables label-free surface-marker profiling of single cells. *Analytical Chem* 87: 2988-2995 (2015).
80. Polprasert, C., Schulze, I., Sekeres, M.A., Makishima, H., Przychodzen, B., Hosono, N., Singh, J., Padgett, R.A., Gu, X., Phillips, J.G., Clemente, M., Parker, V., Lindner, D., Dienes, B., Du, Y., Oakley, K., Nguyen, N., Mukherjee, S., Pabst, C., **Godley, L.A.**, Churpek, J.E., Pollyea, D.A., Krug, U., Klein, H.-U., Dugas, M., Berdel, W., Yoshida, K., Shiraiishi, Y., Chiba, K., Tanaka, H.,

- Miyano, S., Ogawa, S., Müller Tidow, C., and Maciejewski, J.P. Inherited and somatic defects in DDX41 in myeloid neoplasms. *Cancer Cell* 27: 658-670 (2015).
81. Yamazaki, J., Jelinek, J., Lu, Y., Cesaroni, M., Madzo, J., Neumann, F., He, R., Taby, R., Vasanthakumar, A., Macrae, T., Ostler, K.R., Kantarjian, H.M., Liang, S., Estecio, M.R., **Godley, L.A.**, and Issa, J.P. *TET2* mutations affect non-CpG island DNA methylation at enhancers and transcription factor binding sites in chronic myelomonocytic leukemia. *Can Res* 75: 2833-2843 (2015).
82. Moen, E.L., Litwin, E., Arnovitz, S., Zhang, X., Zhang, W., Dolan, M.E., and **Godley, L.A.** Characterization of CpG sites that escape methylation on the inactive human X-chromosome. *Epigenetics* 10: 810-818 (2015).
83. Dominguez, P.M., Teater, M., Chambwe, N., Kormaksson, M., Redmond, D., Ishii, J., Vuong, B., Chaudhuri, J., Melnick, A., Vasanthakumar, A., **Godley, L.A.**, Papavasiliou, F.N., Elemento, O., and Shaknovich, R. DNA methylation dynamics of germinal center B cells are mediated by AID. *Cell Rep* 12: 2086-2098 (2015).
84. Churpek, J.E., Pyrtel, K., Kanchi, K.L., Shao, J., Koboldt, D., Miller, C.A., Shen, D., Fulton, R., O'Laughlin, M., Fronick, C., Pusic, I., Uy, G.L., Braunstein, E.M., Levis, M., Ross, J., Elliott, K., Heath, S., Jiang, A., Westervelt, P., DiPersio, J.F., Link, D.C., Walter, M.J., Welch, J., Wilson, R., Ley, T.J., **Godley, L.A.**, and Graubert, T.A. Genomic analysis of germline and somatic variants in familial myelodysplasia/acute myeloid leukemia. *Blood* 126: 2484-2490 (2015).
85. Chapman, C.G., Mariani, C.J., Wu, F., Meckel, K., Butun, F., Chuang, A., Madzo, J., Bissonnette, M.B., Kwon, J.H., and **Godley, L.A.** TET-catalyzed 5-hydroxymethylcytosine regulates gene expression in differentiating colonocytes and colon cancer. *Sci. Rep.* 5: 17568 (2015).
86. Vasanthakumar, A., Zullo, H., Lepore, J.B., Thomas, K., Young, N., Anastasi, J., Reardon, C.A., and **Godley, L.A.** Epigenetic control of Apolipoprotein E expression mediates gender-specific hematopoietic regulation. *Stem Cells* 33: 3643-3654 (2015).
87. Churpek, J.E., Marquez, R., Neistadt, B., Claussen, K., Lee, M.K., Churpek, M.M., Huo, D., Weiner, H., Bannerjee, M., **Godley, L.A.**, Le Beau, M.M., Pritchard, C.C., Walsh, T., King, M.C., Olopade, O.I., and Larson, R.A. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. *Cancer* 122: 304-311 (2016).
88. Churpek, J.E., Artz, A., Bishop, M., Liu, H., and **Godley, L.A.** Correspondence regarding the consensus statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues. *Biol Blood Marrow Transplant.* 22: 183-184 (2016).
89. Vasanthakumar, A., Arnovitz, S., Marquez, R., Lepore, J., Rafidi, G., Asom, A., Weatherly, M., Davis, E.M., Neistadt, B., Duszynski, R., Vardiman, J.W., Le Beau, M.M., **Godley, L.A.**, and Churpek, J.E. *Brca1* deficiency causes bone marrow failure and spontaneous hematologic malignancies in mice. *Blood* 127: 310-313 (2016).
90. Lewinsohn, M., Brown, A.L., Weinel, L.M., Phung, C., Rafidi, G., Lee, M.K., Schreiber, A.W., Feng, J., Babic, M., Chong, C.E., Lee, Y., Yong, A., Suthers, G.K., Poplawski, N., Aintree, M., Phillips, K., Jaensch, L., Fine, M., D'Andrea, R.J., Lewis, I.D., Medeiros, B.C., Pollyea, D.A., King, M.C., Walsh, T., Keel, S., Shimamura, A., **Godley, L.A.**, Hahn, C.N., Churpek, J.E., and Scott, H.S. Novel germline *DDX41* mutations define families with lower age of MDS/AML onset and lymphoid malignancies. *Blood* 127: 1017-1023 (2016).

91. Laukka, T., Mariani, C.J., Ihantola, T., Cao, J.Z., Hokkanen, J., Kaelin, W.G. Jr, **Godley, L.A.**, and Koivunen, P. Fumarate and succinate regulate expression of hypoxia-inducible genes via TET enzymes. *J Biol Chem* 291: 4256-4265 (2016).
92. Schulze, I., Rohde, C., Scheller-Wendorff, M., Krause, A., Herbst, F., Riemke, P., Hebestreit, K., Tschanter, P., Lin, Q., Linhart, H., **Godley, L.A.**, Glimm, H., Dugas, M., Wagner, W., Berdel, W.E., Rosenbauer, F., and Müller-Tidow, C. Increased DNA methylation of Dnmt3b-targets impairs leukemogenesis. *Blood* 127: 1575-1586 (2016).
93. D'Angelo, C.R., Kocherginsky, M., Pisano, J., Bishop, M.R., **Godley, L.A.**, Kline, J., Larson, R.A., Liu, H., Odenike, O., Stock, W., and Artz, A.S. Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment. *Leuk Lymphoma* 57: 1807-1813 (2016).
94. Garcia-Manero, G., Fenaux, P., Al-Kali, A., Baer, M.R., Sekeres, M.A., Roboz, G.J., Gaidano, G., Scott, B.L., Greenberg, P., Platzbecker, U., Steensma, D.P., Kambhampati, S., Kreuzer, K.A., **Godley, L.A.**, Atallah, E., Collins, R. Jr., Kantarjian, H., Jabbour, E., Wilhelm, F.E., Azarnia, N., Silverman, L.R., and ONTIME study investigators. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. *Lancet Oncol.* 17: 496-508 (2016).
95. DiNardo, C.D., Bannon, S.A., Routbort, M., Franklin, A., Mork, M., Armanios, M., Mace, E.M., Orange, J.S., Jeff-Eke, M., Churpek, J.E., Takahashi, K., Jorgensen, J.L., Garcia-Manero, G., Kornblau, S., Bertuch, A., Cheung, H., Bhalla, K., Futreal, A., **Godley, L.A.**, and Patel, K.P. Evaluation of patients and families with concern for predispositions to hematologic malignancies within the Hereditary Hematologic Malignancy Clinic (HHMC). *Clin Lymphoma Myeloma Leuk* 16: 417-428.e2. (2016).
96. Rojek, K., Nickels, E., Neistadt, B., Marquez, R., Wickrema, A., Artz, A., van Besien, K., Larson, R.A., Lee, M.K., Segal, J.P., King, M.-C., Walsh, T., Shimamura, A., Keel, S.B., Churpek, J.E., and **Godley, L.A.** Identifying inherited and acquired genetic factors involved in poor stem cell mobilization and donor-derived malignancy. *Biol Blood Marrow Transplant.* 22: 2100-2103 (2016).
97. Applebaum, M.A., Jha, A.R., Kao, C., Hernandez, K.M., DeWane, G., Salwen, H.R., Chlenski, A., Dobratic, M., Mariani, C.J., **Godley, L.A.**, Prabhakar, N., White, K., Stranger, B.E., and Cohn, S.L. Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients. *Oncotarget* 7: 76816-76826 (2016).
98. Guidugli, L., Johnson, A.K., Alkorta-Aranburu, G., Nelakuditi, V., Arndt, K., Churpek, J.E., **Godley, L.A.**, Townsley, D., Young, N.S., Fitzpatrick, C., Del Gaudio, D., Das, S., and Li, Z. Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome/acute leukemia predisposition syndromes. *Leukemia* 31: 1226-1229 (2017).
99. Khan, N., Hantel, A., Knoebel, R.W., Artz, A., Larson, R.A., **Godley, L.A.**, Thirman, M.J., Liu, H., Churpek, J.E., King, D., Odenike, O., and Stock, W. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. *Leuk Lymphoma* 58: 1-7 (2017).
100. Wang, A.Y., Weiner, H., Green, M., Chang, H., Fulton, N., Larson, R.A., Odenike, O., Artz, A.S., Bishop, M.R., **Godley, L.A.**, Thirman, M.J., Kosuri, S., Churpek, J.E., Curran, E., Pettit, K., Stock, W., and Liu, H. A phase I study of selinexor in combination with high-dose cytarabine

and mitoxantrone for remission induction in patients with acute myeloid leukemia. *J Hematol Oncol* 11: 4 (2018).

101. Drazer, M.W., Kadri, S., Sukhanova, M., Patil, S.A., West, A.H., Feurstein, S., Calderon, D.A., Jones, M.F., Weipert, C.M., Daugherty, C.K., Ceballos-López, A.A., Raca, G., Lingen, M.W., Li, Z., Segal, J.P., Churpek, J.E., and **Godley, L.A.** Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies. *Blood Adv* 2: 146-150 (2018).
102. Wei, X., Calvo-Vidal, M.N., Chen, S., Wu, G., Revuelta, M.V., Sun, J., Zhang, J., Walsh, M.F., Nichols, K.E., Joseph, V., Snyder, C., Vachon, C.M., McKay, J.D., Wang, S.P., Jayabalan, D.S., Jacobs, L.M., Becirovic, D., Waller, R.G., Artomov, M., Viale, A., Patel, J., Phillip, J.M., Chen-Kiang, S., Curtin, K., Salama, M., Atanackovic, D., Niesvizky, R., Landgren, O., Slager, S.L., **Godley, L.A.**, Churpek, J., Garber, J.E., Anderson, K.C., Daly, M.J., Roeder, R.G., Dumontet, C., Lynch, H.T., Mullighan, C.G., Camp, N.J., Offit, K., Klein, R.J., Yu, H., Cerchetti, L., and Lipkin, S.M. Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma. *Cancer Res.* 78: 2747-2759 (2018).
103. Meisel, M., Hinterleitner, R., Pacis, A., Chen, L., Earley, Z.M., Pierre, J.F., Mayassi, T., Ernest, J.D., Galipeau, H.J., Thuille, N., Bouziat, R., Buscarlet, M., Ringus, D.L., Wang, Y., Li, Y., Dinh, V., Kim, S.M., McDonald, B.D., Zurenski, M.A., Musch, M.W., Furtado, G.C., Lira, S.A., Baier, G., Chang, E.B., Eren, M.A., Weber, C.R., Busque, L., **Godley, L.A.**, Verdú, E.F., Barreiro, L.B., and Jabri, B. Microbial and inflammatory signals drive Tet2-mediated myeloproliferative disease. *Nature* 557: 580-584 (2018).
104. D'Angelo, C.R., Novitsky, B., Mee Lee, S., **Godley, L.A.**, Kline, J., Larson, R.A., Liu, H., Odenike, O., Stock, W., Bishop, M.R., and Artz, A.S. Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. *Leuk Lymphoma* 60: 629-638 (2019).
105. Fan, Y., Artz, A.S., van Besien, K., Stock, W., Larson, R.A., Odenike, O., **Godley, L.A.**, Kline, J., Cunningham, J.M., LaBelle, J.L., Bishop, M.R., and Liu, H. Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant. *Exp Hematol Oncol* 8: 1 (2019).
106. Moshfegh, C.M., Collins, C.W., Gunda, V., Vasanthakumar, A., Cao, J.Z., Singh, P.K., **Godley, L.A.**, and Case, A.J. Mitochondrial superoxide disrupts the metabolic and epigenetic landscape of CD4+ and CD8+ T-lymphocytes. *Redox Biol.* 27: 101141 (2019).
107. Jeong, J.J., Gu, X., Nie, J., Sundaravel, S., Liu, H., Kuo, W.L., Bhagat, T.D., Pradhan, K., Cao, J., Nischal, S., McGraw, K.L., Bhattacharyya, S., Bishop, M.R., Artz, A., Thirman, M.J., Moliterno, A., Ji, P., Levine, R.L., **Godley, L.A.**, Steidl, U., Bieker, J., List, A.F., Sauntharajah, Y., He, C., Verma, A., and Wickrema, A. Cytokine regulated phosphorylation and activation of TET2 by JAK2 in hematopoiesis. *Cancer Discov.* 9: 778-795 (2019).
108. Applebaum, M.A., Barr, E.K., Karpus, J., Nie, J., Zhang, Z., Armstrong, A.E., Uppal, S., Sukhanova, M., Zhang, W., Chlenski, A., Salwen, H.R., Wilkinson, E., Dobratic, M., Grossman, R., **Godley, L.A.**, Stranger, B.E., He, C., and Cohn, S.L. 5-Hydroxymethylcytosine profiles are prognostic of outcome in neuroblastoma and reveal transcriptional networks that correlate with tumor phenotype. *JCO Precis Oncol.* 2019: 3 (2019).
109. Luo, X., Feurstein, S., Mohan, S., Porter, C.C., Jackson, S.A., Keel, S., Chicka, M., Brown, A.L., Kesslerwan, C., Agarwal, A., Luo, M., Li, Z., Ross, J.E., Baliakas, P., Pineda-Alvarez, D.,

- DiNardo, C.D., Bertuch, A.A., Mehta, N., Vulliamy, T., Wang, Y., Nichols, K.E., Malcovati, L., Walsh, M.F., Rawlings, L.H., McWeeney, S.K., Soulier, J., Raimbault, A., Routbort, M.J., Zhang, L., Ryan, G., Speck, N.A., Plon, S.E., Wu, D., and **Godley, L.A.** ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline *RUNX1* variants. *Blood Adv.* 3: 2962-2979 (2019).
110. Brown, A.L., Hahn, C., Hiwase, D., Godley, L.A., and Scott, H.S. Correct application of variant classification guidelines in germline *RUNX1* mutated disorders to assist clinical diagnosis. *Leuk Lymphoma* 61: 246-247 (2020).
111. Wu, D., Luo, X., Feurstein, S., Kesserwan, C., Mohan, S., Pineda-Alvarez, D., and **Godley, L.A.** on behalf of the collaborative group of ASH-ClinGen Myeloid Malignancy Variant Curation Expert Panel. How I curate: Applying American Society of Hematology-Clinical Genome Myeloid Malignancy Variant Curation Expert Panel rules for *RUNX1* variant curation for germline predisposition to myeloid malignancies. *Haematol* 105: 870-887 (2020).
112. Applebaum, M.A., Barr, E.K., Karpus, J., West-Szymanski, D.C., Oliva, M., Sokol, E.A., Zhang, S., Zhang, Z., Zhang, W., Chlenksi, A., Salwen, H.R., Wilkinson, E., Dobratic, M., Grossman, R.L., **Godley, L.A.**, Stranger, B.E., He, C., Cohn, S.L. 5-hydroxymethylcytosine profiles in circulating cell-free DNA associate with disease burden in children with neuroblastoma. *Clin Cancer Res.* 26: 1309-1317 (2020).
113. Cahill, K.E., Karimi, Y.H., Karrison, T.G., Jain, N., Green, M., Weiner, H., Fulton, N., Kadri, S., **Godley, L.A.**, Artz, A.S., Liu, H., Thirman, M.J., Le Beau, M.M., McNERney, M.E., Segal, J., Larson, R.A., Stock, W., and Odenike, O. A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. *Blood Adv.* 4: 599-606 (2020).
114. Brown, A.L., Arts, P., Carmichael, C.L., Babic, M., Dobbins, J., Chong, C.E., Schreiber, A.W., Feng, J., Phillips, K., Wang, P.P.S., Ha, T., Homan, C.C., King-Smith, S.L., Rawlings, L., Vakulin, C., Dubowsky, A., Burdett, J., Moore, S., McKavanagh, G., Henry, D., Wells, A., Mercorella, B., Nicola, M., Suttle, J., Wilkins, E., Li, X.C., Michaud, J., Brautigan, P., Cannon, P., Aintree, M., Jaensch, L., Fine, M., Butcher, C., D'Andrea, R.J., Lewis, I.D., Hiwase, D.K., Papaemmanuil, E., Horwitz, M.S., Natsoulis, G., Rienhoff, H.Y., Patton, N., Mapp, S., Susman, R., Morgan, S., Cooney, J., Currie, M., Popat, U., Bochtler, T., Izraeli, S., Bradstock, K., **Godley, L.A.**, Krämer, A., Fröhling, S., Wei, A.H., Forsyth, C., Mar Fan, H., Poplawski, N.K., Hahn, C.N., and Scott, H.S. *RUNX1*-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. *Blood Adv.* 4: 1131-1144 (2020).
115. Qiu, Z., Lin, A.P., Jiang, S., Elkashef, S.M., Myers, J., Srikantan, S., Sasi, B., Cao, J.Z., **Godley, L.A.**, Rakheja, D., Lyu, Y., Zheng, S., Madesh, M., Shio, Y., Dahia, P.L.M., and Aguiar, R.C.T. MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome. *Cell Chem Biol.* 27: 538-550 (2020).
116. Cao, J.Z., Liu, H., Wickrema, A., and **Godley, L.A.** HIF-1 directly induces *TET3* expression to enhance 5-hmC density and induce erythroid gene expression in hypoxia. *Blood Adv.* 4: 3053-3062 (2020).
117. Kewan, T., Noss, R., **Godley, L.A.**, Rogers, H.J., and Carraway, H.E. Inherited thrombocytopenia caused by germline *ANKRD26* mutation should be considered in young patients with suspected myelodysplastic syndrome. *J Investig Med High Impact Case Rep.* 8: 2324709620938941 (2020).

118. Feurstein, S., Adegunsoye, A., Mojsilovic, D., Vij, R., West DePersia, A.H., Rajagopal, P.S., Osman, A., Collins, R.H., Kim, R.H., Gore, S.D., Greenberg, P., **Godley, L.A.**, Li, Z., Del Gaudio, D., Subramanian, H.P., Das, S., Walsh, T., Gulsuner, S., Segal, J.P., Husain, A.N., Gurbuxani, S., King, M.C., Streck, M.E., and Churpek, J.E. Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations. *Blood Adv* 4: 4873-4886 (2020).
119. Trottier, A.M., Druhan, L.J., Kraft, I.L., Lance, A., Feurstein, S., Helgeson, M., Segal, J.P., Das, S., Avalos, B.R., and **Godley, L.A.** Heterozygous germ line *CSF3R* variants as risk alleles for development of hematologic malignancies. *Blood Adv* 4: 5269-5284 (2020).
120. Toubiana, S., Larom, G., Smoom, R., Duszynski, R.J., **Godley, L.A.**, Francastel, C., Velasco, G., and Selig, S. Regulation of telomeric function by DNA methylation differs between humans and mice. *Hum Mol Genet*. 29: 3197-3210 (2020).
121. Cavalcante de Andrade Silva, M., Katsumura, K.R., Mehta, C., Velloso, E.D.R.P. Bresnick, E.H., and **Godley, L.A.** Breaking the spatial constraint between neighboring zinc fingers: a new germline mutation in GATA2 deficiency syndrome. *Leuk* 35: 264-268 (2021).
122. Roloff, G.W., **Godley, L.A.**, and Drazer, M.W. Assessment of technical heterogeneity among diagnostic tests to detect germline risk variants for hematopoietic malignancies. *Genet Med*. 23: 211-214 (2021).
123. Feurstein, S., Churpek, J.E., Walsh, T., Keel, S., Hakkarainen, M., Schroeder, T., Germing, U., Geyh, S., Heuser, M., Thol, F., Pohlkamp, C., Haferlach, T., Gao, J., Owen, C., Goehring, G., Schlegelberger, B., Verma, D., Krause, D.S., Gao, G., Cronin, T., Gulsuner, S., Lee, M., Pritchard, C.C., Subramanian, H.P., del Gaudio, D., Li, Z., Das, S., Kilpivaara, O., Wartiovaara-Kautto, U., Wang, E.S., Griffiths, E.A., Döhner, K., Döhner, H., King, M.-C., and **Godley, L.A.** Germline variants drive myelodysplastic syndrome in young adults. *Leukemia*, accepted (2021).

Book Chapters

1. **Godley, L.A.** and Larson, R.A. "The syndrome of therapy-related myelodysplasia and myeloid leukemia" in *The Myelodysplastic Syndromes: Pathobiology and Clinical Management*. Ed. J. M. Bennett. Marcel Dekker, Inc., 139-176 (2002).
2. **Godley, L.A.** and Vogelzang, N.J. "The use of systemic chemotherapy in the treatment of metastatic renal cell carcinoma" in *Renal and Adrenal Tumours: Biology and Management*. Eds. A. Belldegrun, R. Figlin, E. Darracott Vaughn, Jr., A. Ritchie, and T. Oliver. Oxford Medical Publications, 367-380 (2003).
3. **Godley, L.A.** and Le Beau, M.M. "Cytogenetics and Gene Rearrangements" in *Williams Hematology*, 7th ed. Eds. M. A. Lichtman, E. Beutler, T. J. Kipps, U. Seligsohn, K. Kaushansky, and J. T. Prchal. McGraw Hill Professional, 137-150 (2006).
4. **Godley, L.A.** and Le Beau, M.M. "Therapy-Related AML" in *Contemporary Hematology: Acute Myelogenous Leukemia*. Ed. Judith E. Karp. The Humana Press, 71-95 (2007).
5. **Godley, L.A.** and Larson, R.A. "Therapy-related Myelodysplastic Syndrome and Myeloid Leukemia" in *Myelodysplastic Syndrome: Pathology and Clinical Management*, 2nd ed. Ed. David P. Steensma. Informa Healthcare, 173-194 (2008).
6. Caces, D.B.D., van Besien, K., Artz, A.S., and **Godley, L.A.** "Donor policies for hematopoietic stem cell transplantation" (Chpt 25) in *Stem Cells and Cancer Stem Cells*, Vol. 6. Ed. M.A. Hayat. Springer Science (2012).

7. Mariani, C.J., Moen, E.L., Macrae, T., Daunov, M., Ostler, K.R., and **Godley, L.A.** "Chromosomal dynamics and stability" Eds. Walter Stadler and Richard Winters. Demos Medical Publishing, 45-65 (2014).
8. Raca, G., Sukhanova, M., and **Godley, L.A.** "Acute myeloid leukemia in adults. Prognosis-Cytogenetics and beyond" in Expert Clinical Perspective on Diagnosis and Management of Cancer. Eds. Syed Abutalib and Maurie Markman. Wiley Publishing, Inc., 51-57 (2014).
9. **Godley, L. A.**, Sukhanova, M., Raca, G., and Le Beau, M. M. "Cytogenetics and Genetic Abnormalities" in *Williams Hematology*, 9th ed. Eds. K. Kaushansky, J.T. Prchal, O.W. Press, M. A. Lichtman, M. Levi, L.J. Burns, and M.A. Caligiuri. McGraw Hill Education, 173-190 (2016).

Invited and Review Articles

1. **Godley, L.A.** Clinical Trials and End-of-Life Decision Making, Virtual Mentor, November 2004. [HTTP://www.ama-assn.org/ama/pub/category/13185.html](http://www.ama-assn.org/ama/pub/category/13185.html). Accessed November 1, 2004.
2. Mattison, R.J., Ostler, K.R., Locke, F.L., and **Godley, L.A.** Implications of *FLT3* mutations in the therapy of acute myeloid leukemia. *Reviews on Recent Clinical Trials* 2: 135-141 (2007). [peer-reviewed]
3. Kihlslinger, J.E. and **Godley, L.A.** The use of hypomethylating agents in the treatment of hematologic malignancies. *Leuk Lymphoma* 48: 1676-1695 (2007). [peer-reviewed]
4. **Godley, L.A.** HMGA2 levels in CML: relective of miRNA gene regulation in a hematopoietic tumor? *Leuk Lymphoma* 48: 1898-1899 (2007).
5. Donepudi, S., Mattison, R.J., Kihlslinger, J.E., and **Godley, L.A.** Modulators of DNA methylation and histone acetylation. *Update on Cancer Therapeutics* 2: 157-169 (2007). [peer-reviewed]
6. **Godley, L.A.** and Larson, R.A. Therapy-related myeloid leukemia. *Seminars in Oncol* 35: 418-429 (2008).
7. Fackenthal, J.D. and **Godley, L.A.** Aberrant RNA splicing and its functional consequences in cancer cells. *Disease Models and Mechanisms* 1: 37-42 (2008). [peer-reviewed]
8. **Godley, L.A.** Deletion of the der(9q) in chronic myeloid leukemia: the controversy continues. *Leuk Lymphoma* 50: 871-872 (2009).
9. Garcia, J.S., Jain, N., and **Godley, L.A.** An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes. *Oncotargets and Therapy* 3: 1-13 (2010).
10. **Godley, L.A.**, and van Besien, K. The next frontier for stem cell transplant: finding a donor for all. *JAMA* 303: 1421-1422 (2010). [peer-reviewed]
11. Smith, S.M., Anastasi, J., Cohen, K.S., and **Godley, L.A.** Beyond Burkitt Lymphoma: The impact of MYC-expression in lymphoma biology. *Blood Cells, Molecules and Diseases* 45: 317-323 (2010). [peer-reviewed]
12. Larson, Sarah M. and **Godley, L.A.** Getting to the root of the stem cell in mutated chronic myeloid leukemia. *Leukemia and Lymphoma*, 51: 2147-2148 (2010).
13. **Godley, L.A.** and Mondragón, A. Preference by exclusion. *Science* 331: 1017-1018 (2011).

14. **Godley, L.A.**, Cunningham, J., Dolan, M.E., Huang, R.S., Gurbuxani, S., McNerney, M.E., Larson, R.A., Leong, Lussier, Y., Onel, K., Odenike, O., Stock, W., White, K.P., and Le Beau, M.M. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. *Seminars in Oncol* 38: 215-224 (2011).
15. Odenike, O., Thirman, M.J., Artz, A.S., **Godley, L.A.**, Larson, R.A., and Stock, W. Gene mutations, epigenetic dysregulation and personalized therapy in myeloid neoplasia: are we there yet? *Seminars in Oncol* 38: 196-214 (2011).
16. **Godley, L.A.** and Le Beau, M.M. The histone code and treatments for acute myeloid leukemia. *N Engl J Med* 366: 960-961 (2012).
17. **Godley, L.A.** Profiles in Leukemia. *N Engl J Med* 366: 1152-1153 (2012).
18. King, D. and **Godley, L.A.** Alterations in covalent cytosine modifications in AML. *The Hematologist* 9: 1-5 (2012).
19. **Godley, L.A.** A drug that stops traffic at the nuclear border. *Blood* 120: 1759-1760 (2012).
20. Madzo, J., Vasanthakumar, A., and **Godley, L.A.** Perturbations of 5-hydroxymethylcytosine patterning in hematologic malignancies. *Semin Hematol* 50: 61-9 (2013).
21. Moen, E.L., **Godley, L.A.**, Zhang, W., and Dolan, M.E. Pharmacogenomics of chemotherapeutic susceptibility and toxicity. *Genome Med* 4:90 (2012).
22. Goodell, M.A. and **Godley, L.A.** Perspectives and future directions for epigenetics in hematology. *Blood* 121: 5131-5137 (2013).
23. Nickels, E.M., Soodalter, J., Churpek, J.E., and **Godley, L.A.** Recognizing familial myeloid leukemia in adults. *Therapeutic Advances in Hematology* 4: 254-269 (2013).
24. Mariani, C.J., Madzo, J., Moen, E.L., Yesilkanal, A., and **Godley, L.A.** Alterations of 5-hydroxymethylcytosine in human cancers. *Cancers* 5: 786-814 (2013).
25. West, A.H., **Godley, L.A.**, and Churpek, J.E. Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations. *Ann NY Acad Sci.* 1310: 111-118 (2014).
26. Vasanthakumar, A. and **Godley, L.A.** On the origin of leukemic species. *Cell Stem Cell* 14: 421-422 (2014).
27. **Godley, L.A.** Inherited predisposition to AML. *Seminars in Hematology* 51: 306-321 (2014).
28. Jasielc, J., Saloura, V., and **Godley, L.A.** The mechanistic role of DNA methylation in myeloid leukemogenesis. *Leukemia* 28: 1765-1773 (2014).
29. Churpek, J.E. and **Godley, L.A.** Familial leukemia and myelodysplastic syndromes. *Up to Date*, 2014.
30. Moen, E., Mariani, C., Zullo, H., Jeff-Eke, Meselle, Litwin, E., Nikitas, J., and **Godley, L.A.** New themes in the biological functions of 5-methylcytosine and 5-hydroxymethylcytosine. *Immunological Reviews* 263: 36-49 (2015).

31. Vasanthakumar, A. and **Godley, L.A.** 5-Hydroxymethylcytosine in cancer: significance in diagnosis and therapy. *Cancer Genet.* 208:167-77 (2015). Correction published: *Cancer Genet.* 209:177 (2016).
32. The University of Chicago Hematopoietic Malignancies Cancer Risk Team: Drazer, M.W., Feurstein, S., West, A.H., Jones, M.F., Churpek, J.E., and **Godley, L.A.** How I diagnose and manage individuals at risk for inherited myeloid malignancies. *Blood* 128: 1800-1813 (2016).
33. Feurstein, S., Drazer, M.W., and **Godley, L.A.** Genetic predisposition to leukemia and other hematologic malignancies. *Semin Oncol* 43: 598-608 (2016).
34. **Godley, L.A.** *DNAJC21*: the new kid on the SDS block. *Blood* 129: 1413-1414 (2017).
35. Feurstein, S. and **Godley, L.A.** Germline *ETV6* mutations and predisposition to hematological malignancies. *Int J Hematol* 106: 189-195 (2017).
36. **Godley, L.A.** and Shimamura, A. Genetic predisposition to hematologic malignancies: management and surveillance. *Blood* 130: 424-432 (2017).
37. Brown, A.L., Churpek, J.E., Malcovati, L., Dohner, H., and **Godley, L.A.** Recognition of familial myeloid neoplasia in adults. *Semin Hematol.* 54: 60-68 (2017).
38. McNERNEY, M.E., **Godley, L.A.**, and Le Beau, M.M. Therapy-related myeloid neoplasms: when genetics and environment collide. *Nat Rev Cancer* 17: 513-527 (2017).
39. **Godley, L.A.** Mutant RUNX1 and histone tales. *Blood* 130: 2156-2157 (2017).
40. Desai, A.V., Perpich, M. and **Godley, L.A.** Clinical assessment and diagnosis of germline predisposition to hematopoietic malignancies: The University of Chicago Experience. *Front Pediatr* 5: 252 (2017).
41. Akpan, I.J., Osman, A.E.G., Drazer, M.W., and **Godley, L.A.** Hereditary myelodysplastic syndrome and acute myeloid leukemia: Diagnosis, questions, and controversies. *Curr Hematol Malig Rep.* 13: 426-434 (2018).
42. Busque, L. and **Godley, L.A.** *MBD4*: guardian of the epigenetic galaxy. *Blood* 132: 1468-1469 (2018).
43. Osman, A.E.G., Anderson, J., Churpek, J.E., Christ, T.N., Curran, E., **Godley, L.A.**, Liu, H., Thurman, M.J., Odenike, T., Stock, W., and Larson, R.A. Treatment of acute promyelocytic leukemia in adults. *J Oncol Pract* 14: 649-657 (2018).
44. Obrochta, E. and **Godley, L.A.** Identifying patients with genetic predisposition to acute myeloid leukemia. *Best Pract Res Clin Haematol.* 31: 373-378 (2018).
45. Trottier, A.M., Cavalcante de Andrade Silva, Li, Z, and **Godley, L.A.** Somatic mutation panels: Time to clear their names. *Cancer Genet* 235-236: 84-92 (2019).
46. **Godley, L.A.** FouNder mutations confer risk for leukemias. *Blood* 133: 2636-2638 (2019).
47. Kraft, I.L. and **Godley, L.A.** Identifying potential germline variants from sequencing hematopoietic malignancies. *Blood* 136: 2498-2506 (2020).

48. Trottier, A.M. and **Godley, L.A.** Inherited predisposition to haematopoietic malignancies: overcoming barriers and exploring opportunities. *Br J Haematol in press* (2020).
49. Roloff, G.M., Drazer, M.W., and **Godley, L.A.** Inherited susceptibility to hematopoietic malignancies in the era of precision oncology. *JCO Prec Oncol* 5: 107-122 (2021).
50. **Godley, L.A.** Germline mutations in MDS/AML predisposition disorders. *Curr Opin Hematol in press* (2021).

INTRAMURAL SERVICE

The University of Chicago- Committees

- 2003-2007 Intern Selection Committee
- 2009 Drug Screening Platform Committee
- 2005-present Hematology/Oncology Fellowship Selection Committee
- 2009-present Faculty Animal Advisory Committee
- 2016 Member, Committee on Appointments and Promotions
- 2017 Member, Advisory Committee on Assistant Professors

The University of Chicago- Clinical

I am a physician-scientist with a clinical specialization in hematology and research interests in the epigenetic changes that drive hematopoiesis and cell differentiation as well as identifying germline mutations that predispose to hematopoietic malignancies.

2003-present Leukemia and Stem Cell Transplant Programs (4-6 weeks of in-patient service, currently 4 weeks, 6 weeks 2014-2016)

2003-present Hematology Clinic (one half-day of clinic per week, 12 months per year; joint "clonal hematopoiesis" clinic with cardiology one half-day per month)

TEACHING EXPERIENCE

Past

- 1986-1988 Harvard Summer School, Cambridge, MA
Taught class of 15 students in an intensive eight week condensation of *Precalculus Mathematics*.
- 1986-1988 Harvard and Radcliffe Colleges, Cambridge, MA
Taught *Precalculus Mathematics* to a class of 14 Harvard undergraduates. Course material included algebra, trigonometry, logarithms, and functions. Responsibilities included preparing lectures, grading homework, holding office hours and review sessions, and creating exams. Taught four semesters.
- 1992 University of California, San Francisco, San Francisco, CA
Teaching fellow for first year medical students in introductory biochemistry class.

Current

Medical School- Didactic

- 2002-present Preceptor for Clinical Skills 2: Physical Diagnosis course
Teach four medical students the principles of patient interviewing, oral presentations, and the physical examination of patients.
- 2002-2016 Lecturer for Clinical Pathophysiology and Therapeutics I course
Present a one hour lecture on hypochromic anemias, followed by precepting the accompanying laboratory session.

Graduate School- Didactic

- 2002-present Lecturer for Cancer Biology II course
Present two one and a half hour lectures on the role of DNA methylation in cancer biology to graduate students in the Cancer Biology Program.

2012-2013 Lecturer for Epigenetics in Cancer course
Present two one and a half hour lectures on the role of epigenetic alterations in cancer to enrolled graduate and undergraduate students.

Resident/Fellow- Clinical

Supervise one medical resident and one medical intern during inpatient clinical service

Supervise 1-2 Hematology/Oncology fellows during weekly outpatient clinic

TRAINEES

In the Laboratory

Visiting Scholars

2007, 2008 (summers only)

2015 Stacey Payne Raimondi, Ph.D. (Assistant Professor, Elmhurst College, Elmhurst, IL)
2015 Simone Feurstein (Hematology/Oncology Fellow, University of Ulm, Germany)
2018 Pamela Mora (National Cancer Institute, Lima, Peru)
2018 Marcela Cavalcante de Andrade Silva (Hospital Universitario Maceio, Brazil)

Post-doctoral, clinical fellows, and residents

2003-2005 Ozden Ozer, M.D. (Hematopathology fellow)
2006-2007 Gopal Patel, Ph.D. (post-doctoral fellow)
2007-2013 Jozef Madzo, Ph.D. (post-doctoral fellow and staff scientist)
2009-2011 Jacqueline S. Garcia, M.D. (Internal Medicine resident)
Recipient of the American Society of Hematology
Trainee Research Award, 2010.
2011-2012 Laurie Risner, PhD (post-doctoral fellow)
2011-2012 Jane E. Churpek, M.D. (Hematology/Oncology fellow)
2007-2015 Aparna Vasanthakumar, Ph.D. (post-doctoral fellow)
2013-present Michael Drazer, M.D. (Internal Medicine resident; Hematology-Oncology Fellow;
Damon Runyon Physician-Scientist Training Award)
2016-2018 Sakshi Uppal, Ph.D. (post-doctoral fellow)
2016-present Simone Feurstein, M.D., Ph.D. (post-doctoral fellow; Chicago Fellow)
2017-2018 Kiran Tawana, M.D., Ph.D. (post-doctoral fellow)
2017-2018 Joshua Bell, Ph.D. (post-doctoral fellow)
2018-2019 Amy Trottier, M.D. (post-doctoral fellow)
2017-2019 Brian Ruhle, M.D. (Surgery resident)
2018-present Afaf Osman, M.D. (Hematology-Oncology fellow)
2018-2019 Imo Akpan, M.D. (Hematology-Oncology fellow, 90%; Instructor 10%)
2019-present Lorraine Canham, M.D., (Pediatric Hematology-Oncology fellow)

Graduate and medical students

2004, 2007-2010

Jesus Exposito-Cespedes (medical student)
2006-2010 Mrinal Shah (graduate student in Cancer Biology)
Recipient of the Busch Scholar-in-Training Award, 2008;
Women in Cancer Research Scholar-in-Training Award, 2009.
2008-2012 Kelly R. Ostler (graduate student in Cancer Biology)
2010-2011 Matthew Zegarek (medical student)
2011; 2012-2013
Eric Nickels (medical student)
2011-2014 Erika L. Moen (graduate student in Cancer Biology)
Attended Lindau Nobel Laureates meeting, Lindau, Germany, June 2014
2010-2015 Christopher Mariani (MD PhD student)
2017 Christopher Miller (medical student from Rosalind Franklin Medical School; received
an American Society of Hematology Minority Medical Student Award)

- 2014-present John Cao (graduate student in Cancer Biology)
2015-present Anastasia Hains (graduate student in Molecular Pathology)
2017-present Stephen Arnovitz (graduate student in Cancer Biology; mentored jointly with Jane E. Churpek and Fotini Gounari)
2017-present Anase Asom (medical student; received an American Society of Hematology Minority Medical Student Award in 2017)
2019-present Maria Acevedo Mendez (University of Illinois medical student; received an American Society of Hematology Minority Medical Student Award in 2019)
2019-2020 Daniel Mendez (Post-Baccalaureate Research Education Program student)

Undergraduate students

- 2006-2008 Yi (Diana) Zhao (The Univ. of Chicago; completed an undergraduate senior thesis)
2008 Jessica DeMaio (Elmhurst College)
2010 Devin Cooper (Washington and Lee University)
2010-2013 Trisha Macrae (The Univ. of Chicago)
2011 Katarzyna Rojek (Yale University)
2012 Krystal Frasier (The Univ. of Chicago)
2012 Patricia Delgado (University of Puerto Rico)
2012-2015 Hayley Zullo (The Univ. of Chicago)
2013 Kenya Thomas (Indiana University)
2013-2015 Meselle Jeff-Eke (The Univ. of Chicago)
2014-2016 Maya Lewinsohn (The Univ. of Chicago)
2014-2017 Anase Asom (The Univ. of Chicago; began Pritzker Medical School in 2017)
2015 John Nikitas (Washington University)
2017-2018 D. Azaii Calderone (The Univ. of Chicago)
2017-2018 Albert Holler (Vanderbilt University)
2018 Ellyn Obrochta (University of Redlands)
2019 Alexandra Woo (Cornell University)
2019 Katherine Sadera (The Univ. of Chicago)
2019-present Sophia Korotev (The Univ. of Chicago)
2019 Adjoa Cofie (Stockton Univ.)
2019 Ulises Nino-Espino (Duke Univ.)

High school teachers and students

- 2007 Yue Liu (student, IL Math and Science Academy)
2008-2009 Bohao Liu (student, IL Math and Science Academy)
2010-2011 Mahi Singh (student, IL Math and Science Academy)
2018-2019 Lidia Ortiz (teacher, Northside College Preparatory High School, Chicago, IL)

In the Clinic

Residents and clinical fellows

- 2007 Sreekanth Donepudi, M.D. (resident)
2007 Ryan Mattison, M.D. (Hematology/Oncology fellow)
2007 Jane Kihslinger-Churpek, M.D. (Hematology/Oncology fellow)
2015 Michael Drazer, M.D. (Hematology/Oncology fellow)

Undergraduate students

- 2006-2009 Elizabet Pujadas
2010-2011 Benjamin Casterline
2010-2011 Josephine Cool
2017-2018 Eric Cormack

Medical Students

- 2009 Sho Yano, Ph.D. (second year medical student)
2018 Nicelio Sanchez-Luege

2018 Frank Wen
2018 Eric Cormack
2018 Austen Ott

Past doctoral committees (students not in my laboratory)

Uddhav Shigdel, The University of Chicago (Chemistry, Advisor: Chuan He, Ph.D.)
Wei Xu, The University of Chicago (Advisor: Barbara Kee, Ph.D.)
Chika Nwachukwu, The University of Chicago (Advisor: Funmi Olopade, M.D.)
Laurie Riesback, Loyola University (Advisor: Nancy Zeleznik-Le, Ph.D.)
Timothy Looney, The University of Chicago (Advisor: Bruce Lahn, Ph.D.)
Fiyinfolu Balogun, The University of Chicago (Advisor: Steve Kron, M.D., Ph.D.)
Tiffany Carr, The University of Chicago (Advisor: Barbara Kee, Ph.D.)
Fern Sha, The University of Chicago (Advisor: Shohei Koide, Ph.D.)
Jennifer Jacobsen, The University of Chicago (Advisor: Barbara Kee, Ph.D.)
Jason Pitt, The University of Chicago (Advisor: Kevin White, Ph.D.)
Matthew Trendowski (PhD student in Cancer Biology, Eileen Dolan Laboratory, Department of Medicine)

Current doctoral committees (students not in my laboratory)

John Coukos (MSTP student, Ray Moelling Laboratory, Department of Chemistry)
Kishan Sangani (MSTP student, Bana Jabri Laboratory, Department of Medicine)
Caraline Sepich (MSTP student, Chuan He Laboratory, Department of Chemistry)

Doctoral students from my laboratory

Mrinal Shah, Ph.D. (2010)
Kelly R. Ostler, Ph.D. (2012)
Erika L. Moen, Ph.D. (2014)
Christopher Mariani, Ph.D. (2015)
John Cao, current doctoral student in my laboratory
Anastasia Hains, current doctoral student in my laboratory
Stephen Arnovitz, current doctoral student in my laboratory, under joint mentorship
Michael Drazer, M.D., current doctoral student in my laboratory